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The science of toxicology is devoted, in large part, to un-
derstanding mechanisms of toxicity so that we can more accu-
rately assess the risk posed by exposure to xenobiotic agents and,
perhaps, intervene in the toxicologic process to mitigate harm.
Dioxin-like chemicals continue to be of great concern as environ-
mental toxicants. About 30 years ago the aryl hydrocarbon
receptor (AHR) was discovered as a specific binding site for
2,3,7,8-tetrachlorodibenzo-p-dioxin. This giant step led to our
current view that essentially all toxic effects of dioxins are AHR-
mediated. The AHR serves as the archetype for understanding
toxicity mediated by other soluble receptors. The fact that toxicity
is receptor-mediated has important implications, especially for
dose–response relationships. In laboratory animals genetic differ-
ences in AHR gene structure lead to profound differences in
responsiveness to dioxin-like chemicals. Humans, however, exhibit
relatively few AHR polymorphisms and these seem to exert only
modest effects on downstream events. Dioxin toxicity is funda-
mentally due to AHR-mediated dysregulation of gene expression.
Our current challenging goal is to determine which dysregulated
genes underlie specific forms of dioxin toxicity. Mapping AHR-
mediated gene expression in a variety of biological systems may
help explain why dramatic differences in susceptibility to dioxin
toxicity exist among laboratory species and why humans appear to
be relatively resistant to adverse effects of dioxins.
Key Words: aryl hydrocarbon receptor; dioxin; 2,3,7,8-tetra-
chlorodibenzo-p-dioxin; gene regulation.
PRELUDE AND DISCLAIMER
This story is a chronicle of the conception, birth, and growth
of aryl hydrocarbon receptor (AHR) research in relation to
toxicology with a focus on evolution of AHR investigations in
my own laboratory. I ask forbearance from readers as well as
from fellow toilers in the AHR field if work from my own
laboratory seems overemphasized or overrepresented. This
article is intended to give a flavor of various aspects of AHR
research rather than a definitive and comprehensive review of
each topic and to be prospective as well as retrospective. Due to
space constraints it won’t be possible to cite the bulk of the
important original contributions made by the numerous labo-
ratories who study the AHR. Please see the excellent reviews by
other investigators, cited in this paper, which provide additional
perspectives on the multitudinous facets of AHR structure and
function.
Before we consider recent developments in the AHR arena, it
may be useful for newcomers to have an overview of how the
AHR field arrived at its current state, illustrated, mainly, by my
own research journey. Journeys are more enjoyable when they
are taken with affable companions. It’s been my good fortune
during the AHR voyage to have been accompanied by many
talented and congenial trainees and collaborators. This narrative
is intended as a tribute to members of my laboratory who con-
tributed so significantly to understanding this intriguing recep-
tor as well as to the international community of AHR scholars
withwhom I’vebeen privileged to interact over the past 30 years.
Research and research careers do not always proceed in
a straightforward, logical, linear fashion. They evolve, just as
do biological systems, via the force of natural selection picking
from among the range of variants. Along the way, there are
serendipitous or fortuitous events (akin to mutations—some
good, some not-so-good) that strongly influence the direction
and the success of our research (Jensen, 2004; Rothstein,
1986). In my case, two lines of research (which on the surface
seemed independent) coalesced, partly by chance, into a 30-
year infatuation with the AHR.
Providential Connections: Estrogens and Polycyclic
Aromatic Hydrocarbons
My original research interest was induction of mammary
cancer by exogenous estrogens. In my Ph.D. thesis research,
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directed by Prof. George Gass, we found that continuous low-
dose administration of the potent synthetic estrogen, diethyl-
stilbestrol (DES), induced mammary carcinoma in more than
95% of mice if they carry the mouse mammary tumor virus. If
mice lack either the virus or the estrogen stimulus, tumor
incidence is very low (Gass et al., 1974; Okey and Gass, 1968).
DES was synthesized in the 1930s from precursors obtained
from coal tar (Dodds et al., 1938). Coal tar (not so co-
incidentally) happens also to be the original source from which
another notorious group of carcinogens was isolated, the
polycyclic aromatic hydrocarbons (PAHs), typified by benzo-
[a]pyrene (BP).
Although DES can be carcinogenic in animal models (and in
humans exposed prenatally to high doses—‘‘DES daughters’’)
(Herbst et al., 1971), DES also found its way into cancer
therapy. Charles Huggins was awarded the Nobel Prize in
Physiology or Medicine in 1966 for his discovery that DES and
other hormonal therapies have value in some cases of advanced
prostate cancer. Huggins also explored hormonal therapy
for breast cancer. To this end, his laboratory was a leader
in developing a remarkable animal model by showing that
PAHs such as 7,12-dimethylbenz[a]anthracene (DMBA) and 3-
methylcholanthrene (3-MC) are superb mammary carcinogens.
These PAHs induce adenocarcinomas in young female
rats within only a few weeks after a single dose (Dao and
Sunderland, 1959; Huggins et al., 1961).
When I took up my first independent research position at the
University of Windsor (Ontario, Canada), I pursued my interest
in the respective roles of the estrogen and the PAH in the
dramatic Huggins model of PAH-induced mammary cancer. It
was bemusing to me, as a new investigator, to find that there
were two (apparently diametrically opposed) mechanistic ex-
planations being floated about for mammary carcinogenesis.
One school held that PAHs were carcinogenic because they
mimic the action of estrogens on mammary epithelium. A
concurrent and competing view flipped this around to propose
that estrogens are carcinogenic because they mimic PAHs—
that is, estrogens are bioactivated into mutagenic metabolites.
Later it would become established that there is a core of truth in
each of these views (see Belous et al., 2007).
Steroids and carcinogenic PAHs bear a passing structural
similarity (Fig. 1). The first known steroid receptor, the estrogen
receptor (ER), was discovered through pioneering work by
Elwood Jensen in the late 1960s (see Jensen, 2004). David
Keightley, my first Ph.D. student, tested the supremely potent
mammary carcinogen, DMBA, to see if it could interact with
the ER and found that DMBA did not compete with estradiol-
17b for binding to the ER (Keightley and Okey, 1973). DMBA
was not a good estrogen but we found that DMBA could
interfere with some ER functions in vivo (Ianicello and Okey,
1976; Keightley and Okey, 1974). At that time we had not
foreseen that a receptor which behaves very much like a steroid
receptor might exist for the PAHs themselves. We will revisit
the estrogen/PAH/AHR story near the end of this review.
Our research on estrogens in relation to mammary carcino-
genesis took on a new dimension when the environmental
movement was spurred in the late 1960s by the disturbing
discovery that pesticides such as dichloro-diphenyl-trichloro-
ethane (DDT) interfere with reproduction in birds (Bitman
et al., 1968; Peakall, 1967) and mammals (Bitman et al., 1968).
Since we were an ‘‘estrogen lab,’’ John Clement, a graduate
student, tested DDT for estrogenic activity in standard bio-
assays and found that the o,p#-DDT isomer has estrogenic
activity but that the commercial mixture (which predominantly
is the p,p#-DDT isomer) exerts ‘‘antiestrogenic’’ effects and
interferes with uterotrophic activity of the natural estrogen,
estradiol-17b (Clement and Okey, 1972).
Because DDT exerts both estrogenic and antiestrogenic
effects, I wanted to find out how this ubiquitous pesticide
would affect development of estrogen-dependent mammary
cancer in rats treated with a PAH. Perhaps this ‘‘real-world’’
exposure to both a pesticide and a PAH carcinogen would be
disastrous to the recipient. In fact, my graduate student, Charles
Silinskas, found that brief pretreatment of female rats with
DDT, at doses as low as 10 ppm, in the diet confers dramatic
protection from DMBA-induced mammary cancer and leuke-
mia (Silinskas and Okey, 1975). This protection appeared to be
due to the ability of DDT to enhance metabolism and
elimination of DMBA (Okey, 1972).
I became intrigued with the phenomenon of induction of
‘‘drug-metabolizing enzymes.’’ I wanted to understand the
induction mechanism and how induction might relate to pro-
tection from environmental carcinogens. It was serendipitous
that I was eligible for a sabbatical leave and I was fortunate
that Daniel Nebert was willing to accept this unknown
2,3,7,8-tetrachlorodibenzo-p-dioxin
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FIG. 1. Representative AHR ligands and estradiol-17b. TCDD is the
prototypical AHR ligand among the group of halogenated aromatic hydro-
carbons (HAHs). 3-MC and BP are major nonhalogenated PAH ligands, widely
studied because of their carcinogenic properties. The structure of estradiol-17b
is included because during the embryonic days of AHR research the potential
interaction of PAHs with ER was being investigated and because there has been
a recent resurgence of interest in estrogens and complex cross-talk between ER
pathways and AHR pathways.
6 OKEY
investigator from a small provincial university into his labora-
tory, then at the National Institute for Child Health and Human
Development, National Institutes of Health (NIH).
Before I continue the tale of my own work during the nascent
days of AHR, it’s necessary to jump back to events beginning
in the 1950s that paved the way for discovery of this captivating
receptor.
ARYL HYDROCARBON RECEPTOR: THE EARLY
YEARS—FROM CONCEPT TO CLONING
Discovery of ‘‘MC-type’’ Induction Lights the Path
Many important nuclear receptors were discovered by
‘‘reverse endocrinology.’’ That is, clones that harbor sequences
similar to those of known nuclear receptors were retrieved from
complementary DNA (cDNA) libraries. However, the protein
products of these novel clones remained ‘‘orphan receptors’’
until their ligands and functions eventually were deciphered.
This genetic pathway to discovery yielded several nuclear
receptors whose acronyms now are widely known in pharma-
cology and toxicology: RAR, RXR, LXR, PPAR, CAR, PXR,
and FXR (reviewed in Evans, 2004; Giguere, 1999; Gustafsson,
1999; Kliewer et al., 1999).
In contrast to the strategy of ‘‘clone first, find function later,’’
the AHR’s discovery preceded the era of receptor cloning and
resulted from efforts to understand the mechanism by which
polycyclic hydrocarbons induce their own metabolism. Allan
Conney, working in the Millers’ laboratory at the University of
Wisconsin in the 1950s, discovered that BP and 3-MC induce
what then was called ‘‘BP hydroxylase.’’ (Later ‘‘BP hydrox-
ylase’’ was designated aryl hydrocarbon hydroxylase [AHH] in
recognition of the fact that many PAHs in addition to BP are
substrates (Nebert and Bausserman, 1970b). Molecular inves-
tigations eventually linked AHH activity to CYP1 enzymes.)
Thephenomenonof ‘‘MC-type’’ inductionbyPAHswasanessen-
tial antecedent to discovery of the AHR. See the engaging auto-
biographical sketch by Conney (2003b) for a full account of the
circumstances which led to his discovery ofMC-type induction.
Genetic Models Plant a Seed that Will Yield a Bountiful
Harvest
Although Prof. Werner Kalow at the University of Toronto
had published his landmark monograph Pharmacogenetics in
1962 (Kalow, 1962), the possibility that genetic factors might
actually matter in drug metabolism and drug response was still
not on the radar screen for most pharmacologists and toxicolo-
gists by 1970. Today pharmacogenetics and pharmacogenomics
have fully penetrated biomedical research as well as the pharma-
ceutical industry; their importancemay seem obvious to younger
investigators but this is a relatively recent enlightenment.
Cell models of AHH induction. Daniel Nebert was an
‘‘early adopter’’ who, at the start of the 1970s, had developed
a well-honed appreciation for the potential power of a genetic
approach to pharmacology and toxicology. Working initially in
Harry Gelboin’s laboratory at the National Cancer Institute-
NIH, Dan Nebert found that induction of BP hydroxylase/AHH
is not confined to liver of intact animals. He developed a very
informative induction model in hamster fetal cell cultures
where many fundamental characteristics of the induction pro-
cess were worked out (Nebert and Bausserman, 1970a; Nebert
and Gelboin, 1968a,b).
A previous in vivo survey pointed to substantial differences
between mouse strains in AHH inducibility by 3-MC (Nebert
and Gelboin, 1969). As a new independent investigator at the
National Institute of Child Health and Human Development,
Dan demonstrated that AHH activity was much more highly
inducible in fetal cells derived from C57BL/6 mice than cells
from DBA/2 mice (Nebert and Bausserman, 1970b), establish-
ing the utility of cell models for exploring pharmacogenetic
aspects of AHH regulation.
In the late 1970s, Oliver Hankinson (University of Califor-
nia) brought a powerful new tool—somatic cell genetics—to
bear on mechanisms regulating induction of AHH. (AHH, by
then was becoming associated with CYP1A1.) The Hankinson
laboratory exposed Hepa-1 mouse hepatoma cells to BP in
culture. BP induces AHH activity in wildtype Hepa-1 cells,
thereby causing them to self-destruct because the induced
enzyme bioactivates BP into cytotoxic metabolites. The rare
mutant cells in the population that are not AHH-inducible
survive; these resistant cells then were selected for further
study to determine the basis of their nonresponsiveness. The
BP-selection process (Hankinson, 1979) and subsequent ge-
netic complementation analyses revealed that, in addition to the
Cyp1a1 gene itself, products of at least two other genes are
required to induce CYP1A1. One of these genes encodes the
AHR (Legraverend et al., 1982).
The biggest payoff from their somatic cell genetic strategy in
the Hankinson laboratory was identification of the other key
regulatory gene product. That is, discovery of a novel protein,
ARNT (aryl hydrocarbon receptor nuclear translocator), which
would turn out to be the essential dimerization partner for the
AHR (Hoffman et al., 1991; Reyes et al., 1992) (see below).
Discovery ofARNT triggered explosivegrowth in theAHRfield
per se aswell as in areas such as hypoxic signalingwhereARNT
(also known as HIF-1b) plays a vital role (Fryer and Simon,
2006) and extending into such diverse areas as vascular tumori-
genesis (Rankin et al., 2005) and type 2 diabetes (Gunton et al.,
2005). Cloning of ARNT and subsequent cloning of the AHR
(seebelow)were instrumental inunveilinganentire familyof reg-
ulatory proteins containingbHLH/PASdomains (Gu et al., 2000).
James Whitlock Jr’s laboratory (Stanford University) used
a fluorescence-activated cell sorter to select cells that are un-
responsive to induction by BP and derived AHR-deficient
mutant cell lines akin to those produced by the Hankinson
laboratory (Miller andWhitlock, 1981; Miller et al., 1983). The
AHR-deficient mutant Hepa-1 cells produced by the Hankinson
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laboratory and the Whitlock laboratory have been invaluable to
other investigators who use them to determine if a particular
response requires the AHR.
In vivo model—the mouse Ah locus. The original Nebert
discovery of a strain difference in AHH induction laid the
foundation for a classic genetic approach to inheritance of
AHH regulation in vivo. Breeding studies in the Nebert
laboratory showed that inheritance of inducibility essentially
is an autosomal dominant trait. The genetic locus controlling
induction was defined as Ah for aromatic hydrocarbon re-
sponsiveness (reviewed in Nebert, 1988, 1989; Nebert et al.,
1981). C57BL/6 mice (Ahrb1 allele in current nomenclature)
constitute the prototype ‘‘responsive’’ strain and DBA/2 mice
(Ahrd allele) the prototype ‘‘nonresponsive’’ strain. The Nebert
laboratory and many other laboratories would go on to show
that genetic differences at the Ah locus (now termed the Ahr
locus) influence sensitivity of mice to a very broad range of
responses to xenobiotic chemicals including mutagenesis, car-
cinogenesis, teratogenesis, and dioxin toxicity (summarized in
Nebert, 1989; Okey et al., 2005b).
The Induction-Receptor Hypothesis Arises
Marshall McLuhan, media guru at the University of Toronto,
inverted the dictum ‘‘seeing is believing’’ to: ‘‘If I hadn’t
believed it, I wouldn’t have seen it.’’ In other words, for some
discoveries, having the conviction that a particular phenome-
non exists is the precondition that permits us to recognize
evidence which supports that phenomenon. For the AHR, the
‘‘belief’’ that there was an induction receptor was based on
a combination of genetic findings along with the precedent of
receptors for other small hydrophobic molecules (i.e., steroids)
which was burgeoning in the 1970s.
The first hint that AHH induction might be mediated by a
receptor goes back to the statement by Nebert and Bausserman
(1970a) who proposed that: ‘‘the process of hydroxylase in-
duction involves a rate-limiting step, which may be the sat-
uration of ‘inducer-binding’ sites in the cell.’’
2,3,7,8-Tetrachlorodibenzo-p-dioxin, a Super-potent
AHH Inducer, Becomes the Ideal Radioligand for the
Receptor Search
The plausibility of the ‘‘induction-receptor’’ hypothesis took
a great leap forward because of 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD). ‘‘Nonresponsive’’ mouse strains are so called
because they do not exhibit AHH induction when treated with
nonhalogenated PAHs such as 3-MC, even at very high doses.
TCDD shifted the focus of investigation away from the enzyme
and toward pathways that regulate AHH expression. TCDD
would soon establish that the ‘‘Ah locus’’ is a regulatory locus
that encodes the AHR.
Alan Poland’s laboratory (then at the University of Ro-
chester) was devoted to determining mechanisms of toxicity of
halogenated aromatic compounds. They found that TCDD,
which they previously showed to be a potent inducer of d-
aminolevulinic acid synthase (Poland and Glover, 1973a), also
was a potent AHH inducer in chick embryo liver (Poland and
Glover, 1973b). Moving to mammals, TCDD proved to be
30,000 times more potent than 3-MC at inducing AHH in rat
liver (Poland and Glover, 1974). Even more revealing was the
ability of TCDD to overcome the ‘‘nonresponsive’’ phenotype
in mice. In collaboration with Dan Nebert’s group, the Poland–
Nebert team found that TCDD was able to induce hepatic AHH
activity in five mouse strains that are nonresponsive to 3-MC
(Poland et al., 1974). The fact that TCDD induced AHH in
‘‘nonresponsive’’ mice led to the conclusion that the P450 gene
encoding the enzyme was normal and to the hypothesis that
nonresponsiveness was due to a mutation which leads to
production of an ‘‘inducer-binding receptor’’ with a reduced
affinity for nonhalogenated aromatic hydrocarbons. Breeding
studies in mice supported this hypothesis (Nebert et al., 1975;
Poland and Glover, 1975), setting the stage for use of radio-
labeled TCDD in the search for the induction receptor.
Alan Poland’s chemistry collaborator at the University of
Rochester, Andrew Kende, prepared [3H]TCDD as the quin-
tessential bait for the receptor fishing expedition. In addition to
its great potency as an AHH inducer, TCDD has the virtue of
being chemically stable and highly resistant to metabolism in
most biological systems in vitro or in vivo. Armed with
[3H]TCDD, Poland, Glover, and Kende brought forth the
eagerly sought first experimental evidence for an induction
receptor in their landmark JBC paper in 1976 (Poland et al.,
1976b). The hypothetical receptor had become real.
The Okey Lab Enters the Induction-Receptor Arena
Adventures with PAH radioligands. In 1976, prior to my
sabbatical leave in the Nebert lab at NIH, [3H]TCDD was not
generally available. My laboratory, therefore, made our initial
foray into the induction-receptor field with tritiated versions
of the nonhalogenated AHH inducers, BP and 3-MC. We at-
tempted to identify a [3H]BP-binding component in C57BL/6
hepatic cytosol that could be saturated at reasonable radioligand
concentrations and that would show specificity when non-
radioactive AHH inducers were introduced as competitors.
Binding profiles, after separating radiolabeled cytosol by
velocity sedimentation on sucrose gradients, revealed a very
large radiolabeled peak with a sedimentation coefficient of
about 4S. There also was a small peak at about 9S but we could
not get ‘‘clean’’ competition by other AHH inducers for the
9S component and did not attempt to publish these data.
In retrospect, the binding component that sedimented at 9S
does, in fact, represent binding of the PAH radioligands to AHR
as we (Okey and Vella, 1982, 1984; Okey et al., 1984) and
Poellinger et al. (1983) would demonstrate in the 1980s by
direct binding studies with [3H]BP, [3H]3-MC and [3H]diben-
zo[a,h]anthracene. The identity and function of the 4S compo-
nent that becomes labeled by [3H]BP and [3H]3-MC remains
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mysterious. The abundant 4S component was tentatively
identified as glycine N-methyltransferase and it was proposed
that the 4S binder mediates CYP1A1 induction (Bhat and
Bresnick, 1997; Raha et al., 1995). However, other studies do
not support a role for the 4S binding component in P450
regulation (Harris et al., 1988; Kamps and Safe, 1987). Most
recently it was reported that b-naphthoflavone, a well-known
CYP1A1 inducer, binds a 4S component but the functional sig-
nificance of this binding for regulating gene expression remains
unclear (Brauze, 2004; Brauze and Malejka-Giganti, 2000).
[3H]TCDD at the NIH. Gregory Bondy, an exceptionally
talented graduate student from my laboratory at the University
ofWindsor, joined me at the Nebert NIH lab for a fewmonths in
the summer of 1978 prior to his entry into medical school. We
applied techniques we previously had used to study ER (Okey
and Bondy, 1977, 1978a,b) to the study of [3H]TCDD binding
in the Nebert Ah-locus mouse model. It may be difficult for
current students to envision this Paleozoic era in receptor
research when the only method available to identify and char-
acterize soluble receptors was by reversibly tagging themwith a
dissociable radioligand. Nevertheless, rapid progress wasmade,
riding on the back of the splendid radioligand, [3H]TCDD.
In addition to the important receptor properties of Kd, Bmax
and specificity that were revealed in Alan Poland’s milestone
1976 paper, we wanted to understand macromolecular structure
of the binding protein. To that end we employed velocity
sedimentation on sucrose density gradients (SDG) along with
ion exchange chromatography. The chromatography experi-
ments were greatly facilitated by the collaboration of the late
Howard Eisen who was a glucocorticoid receptor specialist and
part of the Nebert laboratory. Both the SDG technique and
column chromatography were widely used in the 1970s in
studies of steroid hormone receptors; our use of these methods
reflected our presumption that the dioxin-binding protein was
a type of steroid receptor.
With data gathered primarily by SDGs, we confirmed Alan
Poland’s findings. Namely, that hepatic cytosol from C57BL/6
mice contains a saturable, high-affinity [3H]TCDD binding site
that is selective for compounds known to be AHH inducers and
that this specific binding component was not detectable in
cytosol from genetically nonresponsive DBA/2 mice. It was
Dan Nebert’s wisdom and logic to designate this binding
component the ‘‘AH receptor,’’ since it is the product of the Ah
locus; we introduced the ‘‘AH receptor’’ terminology in our
first paper (Okey et al., 1979).
In the following sections I will concentrate on findings made
by my laboratory but attempt to do justice to the many other
AHR investigators by placing our discoveries in the context of
overall developments in the field.
Nuclear Translocation—Behaving Like a Steroid Receptor
Cloning in the 1990s would reveal that the AHR’s primary
structure does not qualify it for bona fide membership in the
formal nuclear receptor superfamily, notably because the AHR
lacks the zinc-finger domain that typifies steroid receptors.
However, despite belonging to a different gene family, the AHR
behaves very much like a steroid receptor. Because we had
a preconception in the 1970s (based on the steroid receptor
precedent) that liganded AHR should translocate from cyto-
plasm into nucleus, we prepared both cytosol and nuclear
extract from livers of mice injected with [3H]TCDD. We were
rewarded with beautifully symmetrical [3H]TCDD-binding
peaks in both cell fractions (Figs. 2 and 3). Clearly, however,
the cytosolic and nuclear forms of AHR had different sedi-
mentation velocities (Fig. 3). Further experiments would be
required to find out why.
Although nuclear uptake of the [3H]TCDD d AHR complex
could be demonstrated in vivo, (as shown by our experiments
and by William Greenlee’s studies in Alan Poland’s laboratory
at about the same time; Greenlee and Poland, 1979), in vivo
studies are cumbersome. Thus, after I completed my sabbatical
leave in the Nebert laboratory, we collaborated with Michael
Dufresne, a cell biologist at the University of Windsor, to refine
our understanding of the cytosol-to-nucleus translocation pro-
cess in a more tractable system, Hepa-1 cells in culture (Okey
et al., 1980). Cell culture experiments confirmed that sedimen-
tation properties are quite different between cytosolic and
nuclear forms of the AHR. Moreover, we found that trans-
location into the nucleus is a temperature-dependent process.
The nuclear compartment is devoid of AHR until cells are
FIG. 2. Macromolecular snapshot that provides clues to AHR structure.
Our first SDG velocity sedimentation profile of [3H]TCDD binding, performed
by Gregory Bondy in 1978. Hepatic cytosol from a C57BL/6N mouse was
incubated with a concentration of 1nM [3H]TCDD in the presence or absence
of a 100-fold excess of nonradioactive TCDD. When [3H]TCDD is present
alone, there is a clear peak of radioactivity near the middle of the gradient.
Radioactivity in this region is extinguished by excess ‘‘cold’’ TCDD or by
other known CYP1A1 inducers (not shown). The 9S binding component proved
to be the specific TCDD binding site that we designated the AHR (reproduced
from: Okey et al. 1979).
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exposed to a ligand at physiologic temperature. Recent work by
Kawajiri and colleagues shows that the AHR protein contains a
motif for nuclear localization as well as a motif for nuclear ex-
port and that phosphorylation of the nuclear-localization motif
inhibits nuclear uptake of the AHR (Ikuta et al., 1998, 2004a,b).
However, the exact nature of the temperature-dependent step
which is required for nuclear uptake still is not resolved.
Physicochemical Characterization: Appreciating the
AHR as a Macromolecule
Kinetics of ligand binding (Kd and Bmax) can be determined
without knowing anything about the structure of the binding
protein. However, in order to truly understand receptor func-
tion it is imperative to know the receptor’s macromolecular
properties.
When I returned to Canada after completion of my
sabbatical year in the Nebert laboratory I was offered a position
in the Division of Clinical Pharmacology in the Research
Institute at The Hospital for Sick Children, Toronto, where we
continued to investigate multiple facets of the AHR. One
limitation in our research was that the SDG assay we initially
used required overnight centrifugation in a swinging-bucket
rotor that held only six samples. In Toronto, to increase our
analytical capacity, my postdoctoral fellow, Hing Wo Tsui,
developed a 2-h vertical-tube-rotor SDG assay (Tsui and Okey,
1981) that became a mainstay in our research program for
several years and was widely adopted by other laboratories.
Devotees of the author George Orwell might have antici-
pated the dawn of the year 1984 with trepidation. But, in fact,
1984 was a very good year for my laboratory because it saw the
arrival of two exceptionally productive postdoctoral fellows,
Michael Denison and Patricia Harper, and an excellent Ph.D.
student, Rebecca Prokipcak. Mike Denison and Becky Pro-
kipcak immersed themselves in physicochemical characteri-
zation of the AHR while Patricia Harper (a cell biologist
by training) spearheaded our transition toward a molecular
approach to the AHR.
Mike Denison’s hydrodynamic experiments showed that
cytosolic AHRs from Sprague–Dawley rat liver and C57BL/6
mouse liver exist as macromolecular complexes of 250–280
kDa that can be dissociated, under conditions of high ionic
strength, into smaller ligand-binding subunits of about 120 kDa
for rat and 105 kDa for C57BL/6 mouse (Denison et al.,
1986c). These experiments provided the first evidence that the
AHRs from rats and mice are similar but not identical molec-
ular species, a finding that later would be confirmed and ex-
tended in the eras of immunoblotting and cloning.
As described above, our initial experiments in vivo and in cell
culture showed that cytosolic and nuclear forms of AHR have
different sedimentation properties (Okey et al., 1979, 1980).
One possibility was that the nuclear receptor is simply a
monomeric ligand-binding subunit contained within a multi-
meric cytosolic AHR complex and that the ligand-binding
subunit generated when we exposed labeled cytosol to high salt
is the same macromolecule as the nuclear receptor. Further
hydrodynamic analysis by Becky Prokipcak showed that this
simple scenario is not true. Exposure of cytosol to high salt
yields a [3H]TCDD-binding component with a mass of 105
kDa (as seen in the Denison experiments), whereas the form
of receptor recovered by high-salt extraction of nuclei from
cells treated with [3H]TCDD has a mass of about 176 kDa
(Prokipcak and Okey, 1988). Clearly, the nuclear AHR was
not simply the monomeric ligand-binding subunit. Becky went
on to show, by photoaffinity labeling with [3H]TCDD and
electrophoresis under denaturing conditions, that the size of the
ligand-binding component in nuclear AHR is the same as the
ligand-binding component in cytosol (Prokipcak and Okey,
1990). Some additional component would need to be identified
to account for the extra mass of the nuclear form of AHR
detected in our laboratory and others (Elferink et al., 1990;
Gasiewicz et al., 1991). The ‘‘missing piece’’ of the nuclear
complex turned out to be the ARNT protein, later identified by
Oliver Hankinson’s laboratory (Hoffman et al., 1991; Reyes
et al., 1992). The identities of the multiple constituents of the
cytosolic AHR complex would eventually be identified by
several laboratories (see below).
Of course my laboratory was not the only group involved in
this early euphoric phase of AHR characterization. Jan-A˚ke
Gustafsson’s laboratory at the Karolinska Institute, Stockholm,
had great expertise and experience with the glucocorticoid
receptor and turned some attention to the ‘‘TCDD receptor’’ or
FIG. 3. Cytosolic and nuclear forms of AHR have different macromolec-
ular properties. We injected a mouse intraperitoneally with [3H]TCDD, then
removed the liver 2 h later and prepared cytosol and nuclear extracts. Sed-
imentation of the binding component from nuclear extract (near fraction 15) is
much slower than sedimentation of the cytosolic binding component (near
fraction 26). This was the first evidence that the nuclear form of the AHR is
a substantially smaller macromolecular complex than the receptor that initially
binds TCDD in cytosol. See the text for details of this ligand-induced trans-
formation. (Figure from Okey et al., 1979, with permission of the publisher.)
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‘‘dioxin receptor’’ (aka, AH receptor). They first used iso-
electric focusing of [3H]TCDD-labeled rat liver cytosol to
identify a specific binding component that had high affinity and
selectivity for CYP1A inducers (Carlstedt-Duke et al., 1978).
However, partial proteolysis with trypsin was required in order
to focus the specific band; thus it was not possible to determine
physicochemical properties of the native receptor protein.
Lorenz Poellinger (initially in the Gustafsson laboratory) and
Thomas Gasiewicz (University of Rochester) also performed
extensive physicochemical analysis of the AHR and found that
its overall properties were reminiscent of steroid receptors but
with some distinct differences (Gasiewicz and Bauman, 1987;
Gasiewicz and Rucci, 1984; Nemoto et al., 1990; Poellinger
et al., 1982, 1983).
Since the AHR has many physicochemical properties in
common with steroid receptors, both Lorenz Poellinger and
Tom Gasiewicz adapted a steroid receptor technique based on
adsorption to hydroxylapatite to measure [3H]TCDD binding
to AHR (Gasiewicz and Neal, 1982; Poellinger et al., 1985).
The ‘‘HAP’’ method became widely used by many laboratories
as a rapid assay in AHR binding studies.
The ultimate physicochemical characterization for a protein
is to derive a 3D crystallographic structure that will reveal how
the protein functions. The AHR has not yet been crystallized.
However, some insight into AHR 3D structure has been ob-
tained by recent homology modeling based on similarities
in primary structure between the AHR and related proteins
(Pandini et al., 2007). Modeling and site-directed mutagenesis
reveal several structural features that are important to the
ligand-binding function.
Lonely No More: Multiple AHR Partner-Proteins are
Identified
As shown in Figure 4, the AHR resides in cytoplasm until
binding of ligand triggers transformation of the receptor and its
translocation into the cell nucleus. Our early physicochemical
characterization indicated that both the cytosolic and the nuc-
lear forms of AHR are oligomeric complexes composed of
the AHR protein in association with other macromolecules.
Identities of AHR-interacting proteins were resolved, begin-
ning in the late 1980s, through the efforts of many laboratories,
particularly those of Gary Perdew, Christopher Bradfield, and
Lorenz Poellinger.
The heat-shock protein, hsp90, is a major constituent of
the cytosolic complex; its presence was sought in the AHR
complex because hsp90 already was well-known to be a vital
chaperone for steroid receptors. In addition to hsp90 the cyto-
solic AHR complex contains at least two other proteins, ARA9
(also known as AIP or XAP2) which assists in stabilizing the
AHR and retaining it in the cytoplasmic compartment and p23
which appears to aid release of hsp90 from the AHR after
a ligand binds (reviewed in Harper et al., 2006; Petrulis and
Perdew, 2002).
At first glance things seem simpler in the nucleus since the
nuclear AHR complex contains only the AHR itself tightly
FIG. 4. Simplified diagram of the AHR’s mode of action. Prior to ligand binding the AHR resides in cytoplasm where it is bound to hsp90 and additional
chaperone proteins. Ligand binding causes translocation into the nucleus, dissociation of chaperone proteins, and dimerization of AHR with the ARNT protein.
The ligand dAHR d ARNT complex binds to AHREs located in the 5#-flanking region of numerous genes. When occupied by the liganded AHR complex, AHREs
act as transcriptional enhancers to increase the rate of synthesis of specific mRNAs. Note that the liganded AHR also may suppress (downregulate) transcription of
some genes (Tijet et al., 2006) through mechanisms that are not yet clear (Riddick et al., 2004). Induction of Phase I and Phase II enzymes is important because it
strongly influences the balance of bioactivation/detoxication for a wide range of xenobiotic chemicals. However, ‘‘classic’’ forms of dioxin toxicity appear to be
due primarily to dysregulation of genes that encode products other than Phase I/Phase II enzymes. See the text for details. (Diagram modified from Okey et al.,
2005b.)
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bound to its dimerization partner, ARNT. However, the nuclear
ligand d AHR d ARNT complex undergoes a host of protein–
protein interactions with coactivators, coreppressors, chromatin
remodeling proteins, and basal transcription factors (reviewed
in Hankinson, 2005; Kewley et al., 2004; Rowlands et al., 1996;
Swanson, 2002).
The formal family of nuclear receptors (including steroid
receptors) and the bHLH/PAS family (to which the AHR
belongs) are structurally unalike, even though both gene fami-
lies encode ligand-dependent transcription factors. It should not
come as a surprise that many of the chaperones, coactivators,
and corepressor proteins which interact with the AHR also
interact with other receptors. The evolutionary tool-kit contains
component parts that frequently are shared by multiple cellular
pathways.
Identification of Response Elements: the AHR Finds its
Home on DNA
Successful biological regulation requires a degree of specific
recognition at multiple levels in signaling pathways such as
‘‘specificity’’ of a receptor for its ligands. Within the nucleus,
the ligand d AHR d ARNT complex also must be recognized
by specific sites in order to regulate gene expression in an
orderly fashion. The specific nucleotide sequence to which the
nuclear AHR complex binds was first identified by Mike
Denison who, after a very productive stint as a post-doc in my
laboratory, joined Jim Whitlock’s laboratory at Stanford where
they located and sequenced a ‘‘dioxin-responsive element’’ in
the 5#-flanking sequence of the highly inducible mouse Cyp1a1
gene (Denison et al., 1988a,b). This subsequently was corrob-
orated by Yoshiaki Fujii-Kuriyama’s laboratory (then at Tohoku
University, Japan)who termed the enhancer element ‘‘xenobiotic-
responsive element’’ (XRE) (Fujisawa-Sehara et al., 1988). (In
keeping with terminology for the receptor itself, we prefer the
term ‘‘AHRE’’ [AH response element].) The Whitlock labora-
tory went on to extensively describe how the AHR affects the
CYP1A1 promoter and chromatin structure to alter gene ex-
pression (reviewed in Swanson, 2002; Whitlock, 1999).
In collaboration with Mike Denison, Patricia Harper and I
showed that human AHR can be activated by ligand to bind to
the same nucleotide sequence that comprises the mouse AHRE
(Harper et al., 1992). The fundamental mechanism of gene
regulation by the AHR is well-conserved across mammalian
species. The core pentanucleotide AHRE sequence (GCGTG)
occurs frequently within mammalian genomes (Lee et al.,
2006; Sun et al., 2004; Tijet et al., 2006). Recently Oliver
Hankinson’s laboratory reported that the mouse Cyp2s1 gene
contains three overlapping AHRE sequences upstream of the
promoter and three overlapping hypoxia response elements
(HREs) embedded within the region containing the AHREs
(Rivera et al., 2007). The potential complexity of gene
regulation by the AHR is illustrated by the fact that not only
does the AHR dARNT dimer bind to this regulatory region, the
region also binds the HIF-1a d ARNT dimer which is a power-
ful regulator of genes that respond to hypoxia. As we will see
later, the architecture of receptors and their response elements
provide ample opportunity for cross-talk in a potentially very
complex combinatorial fashion.
The AHRE sequence originally identified in the mouse
Cyp1a1 gene probably is the response element for the majority
of AHR-regulated genes. However, induction of CYP1A2 has
perennially been a more complex problem than induction of
CYP1A1. Sogawa et al. (2004) identified a novel enhancer
element in the rat CYP1A2 gene which seems to be the site of
action of the TCDD d AHR d ARNT complex and termed this
response element ‘‘XRE-II.’’ As a twist on the ‘‘standard
model’’ of AHR signaling, the TCDD d AHR d ARNT
complex does not bind directly to the XRE-II response element;
rather, the complex appears to couple to XRE-II through
binding to an unidentified adapter protein which itself binds
XRE-II. My laboratory wondered whether the XRE-II motif
(which we term AHRE-II) was unique to the rat CYP1A2 gene
or whether this element might be involved in other AHR-
mediated gene responses. Paul Boutros, an insightful bioinfor-
maticist in my laboratory, used phylogenetic footprinting to
show that the AHRE-II motif is conserved in at least 36 genes
across the genomes of mouse, rat and human. By gene ex-
pression array analyses we found that about 15 genes which
contain conserved AHRE-II motifs respond to TCDD. Rather
surprisingly, many of these genes that appear to respond
through the AHRE-II element encode ion-channel proteins
and transporters rather than enzymes related to metabolism of
xenobiotic chemicals (Boutros et al., 2004).
AHR Downregulation by its Ligands
Our initial AHR studies in cell culture hinted that treatment
with TCDD causes the total cellular AHR content to decrease
rapidly (Okey et al., 1980). My Ph.D. student, Becky
Prokipcak, performed a thorough accounting of cytosolic and
nuclear forms of AHR in Hepa-1 cells and established, for the
first time, the phenomenon of ligand-induced downregulation
of AHR (Prokipcak and Okey, 1991).
A skilled technical assistant inmy laboratory, JohnGiannone,
then showed that if protein synthesis is blocked with actino-
mycin D or cycloheximide, nuclear AHR levels do not decrease
after cells are exposed to TCDD. These data were the first
evidence that ligand-dependent downregulation of the AHR
likely results from protein degradation involving a short-lived
protease (Giannone et al., 1995). Subsequently, we confirmed
that downregulation of cellular AHR content is not due to a
decrease in AHR messenger RNA (mRNA) but, rather, via
loss of AHR protein while sparing its dimerization partner,
ARNT (Giannone et al., 1998). The laboratories of Richard
Pollenz, Murray Whitelaw, and Qiang Ma then independently
discovered that the mechanism of ligand-induced AHR down-
regulation in cell culture is predominately through the
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ubiquitin-proteasome pathway (Ma and Baldwin, 2000; Pol-
lenz, 2002; Roberts and Whitelaw, 1999).
As described above, downregulation was first discovered in
cell culture. Downregulation also can occur in TCDD-exposed
tissues in vivo (Pollenz et al., 1998; Sommer et al., 1999).
However, a Ph.D. student in my laboratory, Monique Franc,
found that downregulation in rodent liver is transient following
a single TCDD dose in vivo and that after a few days TCDD
actually causes a slight upregulation in AHR mRNA and AHR
protein (Franc et al., 2001a). She also mimicked real-world
environmental/dietary exposure to TCDD and found that AHR
levels remain relatively constant in the face persistent, low-
dose TCDD intake (Franc et al., 2001b).
AHR downregulation presumably represents a cell’s method
of desensitizing itself and preventing excessive stimulation
from potent agonists. Downregulation is dramatic in cell culture
but its transient nature in vivo suggests that most tissues will not
be desensitized following persistent, low-dose TCDD chal-
lenge. So far as we know, resistance to TCDD toxicity cannot be
attributed to sustained downregulation of AHR levels in any
animal species. AHR levels in vivo and in cell culture are
affected by a bewildering variety of factors, including the
receptor’s own ligands; for a recent summary please see Harper
et al. (2006). Our understanding of the ‘‘what regulates the
regulator?’’ remains rudimentary. New factors continually are
being discovered such as the recent reports that Erk kinase
participates in AHR degradation (Chen et al., 2005) and that
NS1BP, a protein which contains a ‘‘kelch’’ domain, may reg-
ulate functional levels of AHR in cells both by tethering AHR to
the cytoskeleton and by influencing proteasomal degradation
(Dunham et al., 2006).
Ubiquitous Expression of the AHR
The original discovery of a specific [3H]TCDD binding site
in mouse liver (Poland et al., 1976b) naturally led to the
question of how widely this new receptor is distributed across
animal species and tissues.
Ontogeny and tissue distribution. As described above, fetal
cells were a valuable early model system to study induction
mechanisms for CYP1 enzymes (Nebert and Gelboin, 1968b).
In addition, TCDD is one of the most potent teratogens
known in rodents. With these motivations, multiple laborato-
ries mapped AHR expression during development.
The developing mouse kidney is exceptionally sensitive to
teratogenesis by TCDD which induces hydronephrosis in an
AHR-dependent fashion (Lin et al., 2001; Mimura et al., 1997;
Peters et al., 1999). Sharon Choi, a Ph.D. student working with
my colleague Patricia Harper in Toronto, found that AHR
mRNA is expressed as early as gestational day-14 in ureter
from C57BL/6 mice (Choi et al., 2006).
There was a surprise when we studied AHR expression and
function in embryonic tissue and cells derived from ‘‘non-
responsive’’ mouse strains. Recall that livers of adult non-
responsive strains are completely refractory to CYP1A
induction by nonhalogenated ligands. In cytosol from tissues
of embryos at 15–19 days gestation, not only were we able to
detect specific binding of the potent agonist, [3H]TCDD, we
also were able to detect some specific binding of the non-
halogenated inducer, [3H]3-MC, to AHR. Moreover, in primary
cultures derived from embryos we found that dose–response
curves for AHH induction by another PAH inducer, benz[a]an-
thracene, were essentially the same for cells from ‘‘nonrespon-
sive’’ mice as they were for ‘‘responsive’’ mice (Harper et al.,
1991a). Ying Huang, a graduate student working with Patricia
Harper and me, found that the AHR in embryonic cells was
indistinguishable from the receptor expressed in adult liver
(Huang et al., 1995). The mechanistic explanation remains
elusive for why embryonic cells from ‘‘nonresponsive’’ strains
can, in fact, respond to PAHs, whereas adult tissues in vivo show
strong separation into ‘‘responsive’’ and ‘‘nonresponsive’’
phenotypes. These experiments in embryonic cell cultures
suggest that the cellular context has a significant influence on
AHR function, possibly because the particular repertoire of
proteins that interact with the AHR differs between embryonic
cells versus cells from adult animals.
During postnatal development, Carlstedt-Duke et al. (1979)
discovered that rat liver AHR levels are highest around
weaning, then wane as animals age. This pattern of highest
hepatic AHR prior to weaning was confirmed for rat by Kahl
et al. (1980) and also found to hold true for mouse and rabbit.
Tom Gasiewicz’s laboratory at the University of Rochester
extended the ontogenic findings by showing that although AHR
levels drop in liver and lung after weaning, levels in thymus
remain elevated for a longer period (Gasiewicz et al., 1984). In
rat prostate, AHR levels are high at birth but undergo a steep
decline even before weaning (Sommer et al., 1999). The
general pattern holds for most rodent tissues: AHR levels are
highest in the younger animals and decline with age. This
pattern suggests that the main biological role of the AHR plays
out during development. Later, the tools of molecular biology
would further illuminate the fundamental biology of the AHR
in relation to development (see below).
After the AHR was discovered in rodent livers, we and other
laboratories surveyed a wide range of mammalian tissues to
determine how broadly this new regulatory protein is distrib-
uted. By radioligand binding and SDG assays, Michelle Mason,
a research assistant in my laboratory, detected AHR in liver,
lung, kidney, intestine, thymus, and prostate of C57BL/6 mice
and Sprague–Dawley rats. By treating mice in vivo with
[3H]TCDD she also found that the [3H]TCDD3AHR complex
could be recovered from nuclei of liver, lung, kidney not only in
responsive C57BL/6 mice but also in ‘‘nonresponsive’’ DBA/2
mice (Mason and Okey, 1982). This was the first definitive
evidence that nonresponsive mice do, in fact, possess an AHR
that is competent to bind ligand and translocate into the nucleus.
Space does not permit a full accounting of each mammalian
tissue that subsequently has been shown to express the AHR.
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Suffice it to say that methods ranging from ligand binding to
mRNA expression profiling reveal that the AHR can be detected
in virtually all mammalian cells and tissues, albeit at widely
varying levels.
A few words on phylogeny. From the earliest days of AHR
research there has been the conundrum of why animals are
endowed with a receptor whose main function appears to be
binding of notoriously toxic and carcinogenic xenobiotic chem-
icals. In the precloning era, mapping the phylogenetic distri-
bution of AHR was one avenue to trying to understand the
receptor’s ‘‘purpose’’ and evolutionary history.
Most toxicology is ‘‘mammalocentric’’ but we and other
laboratories wanted to find out if the AHR was present in
nonmammalian species as well as in a broad spectrum of
mammals (Denison and Wilkinson, 1985). Chick embryo has
a noble history as an excellent model system for studying AHH
induction and other biochemical/toxic effects of halogenated
aromatic hydrocarbons (Hamilton et al., 1983; Poland and
Glover, 1973a,b; Rifkind et al., 1990). In collaboration with
Christopher Wilkinson’s laboratory (Cornell University), Mike
Denison and I found that AHR is expressed in chick embryo as
early as at 5 days of incubation and that levels in chick liver
drop rapidly after hatching, reminiscent of the postnatal
decline in AHR levels in rodents (Denison et al., 1986a). Gail
Bellward’s laboratory (University of British Columbia)
found, using our assay methods, that AHR is not confined to
domestic fowl but also is detectable in feral bird species such
as pigeon, heron, and cormorant (Sanderson and Bellward,
1995).
We also were interested in AHR expression in fish because
trout are highly sensitive to biochemical and toxic effects of
dioxin-like chemicals and PAHs. Our attempts to detect AHR
with our standard [3H]TCDD binding assay in trout liver proved
fruitless, possibly because fish livers contain proteolytic en-
zymes (Hahn et al., 1994) that are adapted to low temperatures
and happily degrade the AHR, even at the 0–4 conditions of the
binding assay. Angela Lorenzen, a graduate student in my lab-
oratory, was first to gain solid evidence that the AHR exists not
only in homeothermic vertebrate species but also in poikilo-
thermic animals. She used a trout hepatoma cell line in culture
to demonstrate binding of [3H]TCDD to cytosolic AHR, trans-
location of the [3H]TCDD dAHR complex into the nucleus and
subsequent induction of AHH activity (Lorenzen and
Okey, 1990). As we would find with recalcitrant AHRs in other
systems, adding molybdate to the buffer was essential to sta-
bilize trout AHR so that specific [3H]TCDD binding could be
detected.
Research over the past three decades indicates that AHR
structure and function are remarkably diverse among verte-
brates and invertebrates. Early physicochemical analyses
suggested that molecular properties of the AHR are similar
among laboratory mammals such as rat, mouse, guinea pig, and
hamster (Gasiewicz and Rucci, 1984; Poellinger et al., 1983);
however, our physicochemical characterization indicated that
rat and mouse AHRs are not identical (Denison et al., 1986c).
Structural differences became even more apparent when
both photoaffinity labeling and the development of anti-AHR
antibodies allowed electrophoretic separation of AHRs from
different animal species under denaturing conditions. These
experiments indicate apparent molecular masses ranging from
95 kDa for the product of the mouse Ahrb1 allele to 146 kDa in
trout (Hahn et al., 1994; Landers et al., 1989; Poland and
Glover, 1987, 1990; Poland et al., 1991; Prokipcak and Okey,
1990). Cloning and sequencing of AHR genes, beginning in the
1990s, confirmed the diversity of molecular masses among
vertebrate AHRs and also revealed that most of the variation in
AHR primary structure resides near the carboxy terminus of the
protein (Gu et al., 2000; Korkalainen et al., 2001).
[3H]TCDD binds with specificity and high affinity to AHR
proteins from a wide range of vertebrate species. However, in
invertebrates, specific [3H]TCDD binding has not been detect-
able in any species out of the many tested (Denison et al., 1985,
1986d; Hahn et al., 1994). Mark Hahn’s laboratory at the
Woods Hole Oceanographic Institution has taken a leading role
in demystifying phylogeny and evolution of the AHR (Hahn,
1998, 2002; Hahn et al., 2006). He proposes that during the
AHR’s evolutionary history it has changed from a protein that
does not bind ligand (invertebrates) to a protein that is a ligand-
activated transcription factor (Hahn et al., 2006). Among the
Hahn laboratory’s other key discoveries is the unexpected
finding, from comparative genomics, that mammals seem
impoverished in regard to how many AHR genes exist within
the genome of an individual species. Genomic sequencing
indicates that mammals have but a single AHR gene, whereas in
certain fish or bird species there may be as many as two to five
genomic sequences that are predicted to encode AHRs. For
a full appreciation of AHR phylogeny and evolution see the
comprehensive and authoritative reviews by Mark Hahn (Hahn,
1998, 2002; Hahn et al., 2006).
The nearly ubiquitous occurrence of AHR in vertebrate
tissues implies that this receptor has important biological
functions. However, as we will see below, AHR knockout, at
least in mice, is not lethal.
Humans, Too, Have AHR
After the discovery and initial characterization of AHR in
rodent tissues, we and other laboratories were eager to de-
termine if humans possess a similar receptor. Such knowledge
would be valuable when attempts are made to incorporate
mechanistic data on dioxin toxicity into human risk assessment.
But the human AHR obstinately refused to cooperate. When we
used assay methods that worked well in rodent cells and tissues,
AHR abundance appeared to be very low or absent in clinical
samples such as lung (Roberts et al., 1986).
We screened many human cell lines and tissues with
disappointing results.With human tissues, there is the challenge
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of obtaining tissues of good quality while adhering to ethical
requirements. Fortunately, human placenta is highly respon-
sive to induction of CYP1A enzymes by cigarette smoke
(Manchester et al., 1984; Nebert et al., 1969; Welch et al.,
1968). David Manchester (a pediatrician and clinical geneticist
at the University of Colorado Health Sciences Center) had a
long-standing interest in regulation of CYP1 enzyme induction
in placenta and had set up a very effective protocol for obtaining
placental tissues of high quality from smoking mothers and
nonsmokers, so we collaborated with David’s laboratory to
investigate AHR in this responsive and available tissue.
We knew that molybdate was a very helpful ingredient in
homogenizing buffers to stabilize various steroid hormone
receptors but we had found that molybdate was not really
necessary to stabilize AHR in rodent livers (Denison et al.,
1986b). Nevertheless, when we modified our procedures with
human placenta by including molybdate in the homogenizing
buffer, we found that molybdate was an elixir that finally
permitted us to detect human AHR (Manchester et al., 1987).
As it turns out, placenta is the human tissue that is perhaps the
most richly endowed with AHR (Manchester et al., 1987; Okey
et al., 1997).
By adding molybdate to the buffer and making other adjust-
ments, we were able to routinely detect AHR in a wide variety
of human tissues. My graduate student, Angela Lorenzen (who
also discovered AHR in trout), used the improved assay to
demonstrate that human tonsils express significant AHR levels
(Lorenzen and Okey, 1991); this is of potential relevance to
human health since atrophy of immune organs such as the
thymus is one of the most sensitive toxic responses to dioxin-
like chemicals in rodents.
Human tissues are useful for obtaining a snapshot of AHR
abundance in diverse tissues from different donors. However,
tissue samples cannot provide much information on the
function of AHR pathways. Thus, we applied our improved
receptor assay to several human cell lines. My Toronto col-
league, Patricia Harper, a genuine cell biologist, directed most
of our studies in cell model systems.
In humans, skin is the most notable target for dioxin toxicity
which manifests as chloracne (Geusau et al., 2001; Panteleyev
and Bickers, 2006), the disfiguring condition that came to
world-wide attention with the poisoning of presidential candi-
date, Victor Yushchenko, in Ukraine in 2005 (Schecter et al.,
2006). As a surrogate for skin cells, we tested the human
squamous cell carcinoma line, A431 and detected good levels
of AHR. In the A431 cells (just as in our previous research with
the mouse Hepa-1 cell line) exposure to TCDD provoked
nuclear translocation of the AHR. Both TCDD and benz[a]-
anthracene induced AHH activity in a classic sigmoidal dose–
response fashion (Harper et al., 1988).
Eve Roberts, a clinician hepatologist, undertook a period of
basic research training in my laboratory and found that HepG2
cells, a human hepatoma cell line widely used as a model for
human hepatic drug metabolism, express AHR and induction
of CYP1A1 (Roberts et al., 1990). In collaboration with
William Waithe and Alan Anderson (L’ Hotel dieu de Quebec),
we found that human peripheral blood lymphocytes, after being
immortalized for growth in culture, displayed the complete
AHR-dependent regulatory mechanism for CYP1A1 induction
(Waithe et al., 1991)
The highest AHR concentration that we’ve detected in any
human cell line is in LS180 colon carcinoma cells (Harper
et al., 1991b). A postdoctoral fellow in my laboratory, Wei Li,
found that LS180 cells exhibit CYP1A2 induction by TCDD or
3-MC (Li et al., 1998). Although CYP1A1 is highly inducible
in a wide variety of mammalian cell lines, CYP1A2 expression
in immortalized cells lines usually is silenced for reasons that
are unclear. Thus, the LS180 cell line constitutes an opportu-
nity to clarify factors that regulate basal CYP1A2 expression
and its AHR-dependent induction.
After early frustrations in our search for human AHR it has
been rewarding to see dozens of reports on AHR expression in
a wide range of human tissues and cell types (summarized in
Okey et al., 1994a). Unquestionably, the AHR is available in
humans to carry out many of the same functions (for better or
worse) that it does in laboratory animals.
Astonishing Range of AHR Ligands
As we have seen, [3H]TCDD became the ideal ligand for
detection and characterization of the AHR. Quite clearly,
however, the binding site is not just a ‘‘dioxin receptor’’ or
‘‘TCDD receptor.’’ Beginning with the first studies with
[3H]TCDD as radioligand, a multitude of chemicals has been
tested to see if they can compete with [3H]TCDD for specific
AHR-binding sites. Competition studies are a mainstay in
determining if a new chemical is a receptor ligand because the
test chemical does not need to be radiolabeled. Through com-
petition studies, the catalog of AHR ligands has been greatly
expanded over the past three decades. However, because
[3H]TCDD binds with very high affinity and dissociates ex-
ceedingly slowly from the AHR, methods used to test for
competition need to be carefully designed to prevent false
negative conclusions, especially when weak ligands are tested
(Denison and Nagy, 2003).
Based on the original experiments with TCDD and closely
related compounds it appeared that the AHR ligand-binding site
had rigid dimensions and that it could accommodate ligands
only if they were highly planar. This view has changed dra-
matically as the catalog of ligands expanded via competition
studies and high-throughput screening assays. Now the AHR is
viewed as one of the ‘‘promiscuous’’ receptors; that is, a receptor
that can effectively bind compounds of diverse shape and chem-
ical properties. Among the ligands from exogenous sources:
halogenated dioxins, dibenzofurans, and polychlorinated bi-
phenyls (PCBs); nonhalogenated PAHs; flavones and carbinols
of plant/dietary origin; therapeutic agents such as omeprazole
(for an excellent review see Denison and Nagy, 2003).
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As I mentioned in the Prelude, my original interest in enzyme
induction was motivated by effects of the pesticide, DDT.
Although we found that commercial grade p,p#-DDT has some
ability to inhibit binding of [3H]TCDD to the AHR (Okey et al.,
1979), it later would turn out that P450 induction by DDT
in vivo most likely is due to binding of its metabolite, dichlor-
odiphenyldichloroethylene to the nuclear receptors CAR and
PXR rather than to the AHR (Coumoul et al., 2002; Wyde et al.,
2003). Thus, although the AHR is ‘‘promiscuous,’’ it is not the
universal receptor for all environmental contaminants.
Endogenous Ligands (or Why did Evolution Endow us
with a Receptor for Toxic Dioxins?)
The question of why a ‘‘dioxin receptor’’ arose in evolution
is inextricably tied to the question of whether there is an
endogenous AHR ligand that regulates ‘‘normal’’ physiologic
functions. From the earliest days of AHR research there has
been a keen interest in identifying the ever-elusive endogenous
ligand. It might be more judicious to say endogenous ligands
because there is no a priori reason why multiple endogenous
agents from different chemical classes might not exist, given
the AHR’s promiscuous reputation for binding structurally di-
verse exogenous compounds (Denison and Nagy, 2003).
Progress in identifying candidate endogenous ligands was
slow during the first two decades of AHR research. However, in
recent years multiple endogenous agents have been shown to
activate AHR pathways. For example, arachidonic acid (AA)
metabolites are released in response to TCDD and it is possible
that some AA metabolites, such as prostaglandins, may act as
AHR agonists (Denison and Nagy, 2003; Rifkind, 2006).
Bilirubin and related tetrapyroles, at high concentrations, can
activate AHR, perhaps serving to induce glucuronosyltransfer-
ase enzymes that conjugate and remove the potentially toxic
products of heme degradation (Denison and Nagy, 2003; Sinal
and Bend, 1997). Ultraviolet (UV) irradiation photo-converts
tryptophan into products that have high affinity for the AHR
and are potent inducers of CYP1A1 (Denison and Nagy, 2003;
Rannug and Fritsche, 2006). Tryptophan also can be con-
verted by the enzyme, aspartate aminotransferase, into indole-3-
pyruvate which spontaneously generates multiple compounds
that can act as AHR agonists (Bittinger et al., 2003).
One approach to identifying endogenous ligands is to prepare
tissue extracts and assay their ability to activate an AHR-
mediated reporter gene system. Song et al. (2002) employed
this approach and isolated, from porcine lung, a compound
whose structure was identified as 2-(1#H-indole-3#-carbonyl)-
thiazole-4-carboxylic acid methyl ester (ITE). Very recently
Henry et al. (2006) confirmed that synthetic ITE is a potent
AHR agonist which induces CYP1A1 in cell culture and in vivo;
however, ITE does not produce dioxin-like teratogenic effects
in mice. This is another instance which reminds us that high-
affinity AHR ligands are not necessarily toxic. We need to find
out why this is true for specific chemical cases and what
features of a chemical ligand are necessary to elicit severe
dioxin-like toxicity.
Of course, an obvious explanation for why a high-affinity
ligand might lack toxicity is that the ligand is an antagonist
rather than an agonist. Savouret et al. (2000) identified 7-
ketocholesterol (7-KC) as an endogenous compound that
competitively binds AHR and inhibits CYP1A1 induction by
TCDD; they propose that 7-KC is a ‘‘protective modulator’’ of
AHR function.
Another contender for the role of endogenous AHR agonist is
modified low-density lipoprotein (LDL). In the 1990s hydro-
dynamic shear stress was found to induce CYP1A1 in cell
culture and initially it was thought that induction was due to
release of AA metabolites (Mufti and Shuler, 1996). However,
very recently the Bradfield laboratory reported that hydrody-
namic shear stress (mimicking blood flow in the vasculature)
modifies an LDL in blood serum such that the LDL becomes an
AHR activator (McMillan and Bradfield, 2007). This may
provide a mechanism for the vital role which the AHR plays in
vascular development (Lahvis et al., 2005).
This brief overview of the range of exogenous and endog-
enous AHR ligands is intended simply to remind us of how
little we understand about the diversity of AHR ligands and
AHR functions. Chris Bradfield’s laboratory divides AHR-
mediated responses into three pathways: (1) adaptive responses
(such as changes in xenobiotic metabolism); (2) toxic pathway;
(3) developmental pathway (Walisser et al., 2004b). Different
ligands may selectively act upon one or more of these pathways
for good or ill (Denison and Nagy, 2003).
To conclude this section, let’s consider what happens if the
AHR is activated in the absence of any ligand. Lorenz
Poellinger’s laboratory deleted the ligand-binding domain and
thereby created an AHR that is constitutively active, i.e., it
stimulates gene expression without any ligand (Kohle et al.,
2002; McGuire et al., 2001). This led to the disturbing
discovery that mice whose AHR is locked into the ‘‘on’’ state
have a shortened life-span and frequently develop stomach
cancer. However, stomach cancer is not commonly seen in
laboratory animals exposed to dioxin-like chemicals and it is
unclear why the constitutively active AHR causes stomach
tumors, whereas the persistent AHR ligand, TCDD, is not an
efficient gastric carcinogen. The constitutively active AHR in
these mice does mimic some other toxic effects of TCDD,
notably thymic atrophy and liver enlargement (Brunnberg et al.,
2006). An independently derived mouse strain, in which the
constitutively active AHR is expressed specifically in T cells,
also shows thymocyte loss without needing to be activated by
TCDD (Nohara et al., 2005).
In the above studies, constitutively active AHRwas produced
through molecular engineering by the investigators. In an
intriguing recent review (Schlezinger et al., 2006), David Sherr
and colleagues summarize evidence which indicates that breast
tumor cells frequently contain significant levels of nuclear AHR
in the absence of any exogenous ligand. This ‘‘constitutive
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activation’’ of AHR might account for elevated CYP1B1 levels
in tumor cells and may be important in pathogenesis. It is not
clear whether the nuclear AHR in breast tumors has been
activated by an endogenous ligand or whether the receptor truly
is ‘‘constitutively activated’’ but this model deserves further
attention, both to understand the regulatory mechanisms and for
its implications for mammary carcinogenesis.
Photoaffinity Labeling as the Path to Purification of
AHR Protein
As mentioned above, early AHR characterization relied on
reversible, high-affinity binding of [3H]TCDD. Much was
learned with this approach. However, with reversible ligands,
unless biochemical procedures are gentle, the radioligand
dissociates from the receptor and leaves the investigator in
the dark. Clearly, it would be advantageous to permanently
attach a radioligand to the AHR.
Photoactivation of [3H]TCDD and [3H]3-MC with UV light
leads to a modest level of covalent attachment of these radio-
ligands to the AHR (deMorais et al., 1994; Landers et al., 1989;
Prokipcak and Okey, 1990). However, a photoaffinity ligand
developed by Andrew Kende and Alan Poland (Poland et al.,
1986), 2-azido-3[125I]iodo-7,8-dibromodibenzo-p-dioxin, was
much more efficient at covalent coupling to the AHR and
possessed very high specific activity. Using this photoaffinity
ligand and various methods of protein fractionation, two
postdoctoral fellows in the Poland laboratory, Gary Perdew
and Chris Bradfield, successfully purified AHR from liver of
C57BL/6 mice (Bradfield et al., 1991; Perdew and Poland,
1988). Most importantly, a partial N-terminal amino acid
sequence was obtained from the purified protein. This, at last,
opened the door to cloning the AHR.
Cloning of Mouse AHR: Revelation of a New Gene Family
The first cloning of mouse AHR cDNA was done the ‘‘old-
fashioned’’ way. The laboratories of Chris Bradfield and
Yoshiaki Fujii-Kuriyama each took advantage of the N-
terminal protein sequence to design oligonucleotide probes
that then were used to screen cDNA libraries (Burbach et al.,
1992; Ema et al., 1992). Prior to AHR cloning, most of us in the
AHR community expected the AHR sequence to be similar to
that of various steroid receptors, many of which already had
been cloned. As it turned out, despite the fact that the AHR and
steroid receptors behave very similarly in their general mode of
action, the AHR belongs to an entirely different gene family.
The closest relative to AHR, based on sequence, is the ARNT
protein, cloned the year prior to AHR cloning in Oliver
Hankinson’s laboratory (Hoffman et al., 1991). AHR and
ARNT contain domains with high sequence similarity to each
other and also domains with sequence similarity to two
Drosophila proteins, Per and Sim (Burbach et al., 1992; Ema
et al., 1992). ARNT, AHR, Per, and Sim became founding
members of the PAS protein superfamily. Proteins such as AHR
and ARNT which contain PAS domains constitute a subgroup
within the broader basic helix–loop–helix (bHLH) superfamily
of transcriptional regulators. bHLH/PAS proteins must di-
merize in order to bind DNA and dimerization is a major
function of the PAS domain (reviewed in Gu et al., 2000;
Kewley et al., 2004). The bHLH/PAS superfamily expanded
rapidly and now includes members with such diverse functions
as clock proteins involved in circadian rhythms and multiple
other physiologic roles (McDearmon et al., 2006).
Purification of mouse AHR and subsequent cDNA cloning
were enormous breakthroughs which allowed the very power-
ful techniques of molecular biology to lift AHR character-
ization to an entirely new level. Initial cloning was rapidly
followed by identification of domains (Fig. 5) in the modular
AHR protein that carry out key functions of ligand binding,
dimerization with ARNT, DNA binding, and transactivation of
gene expression (Dolwick et al., 1993; Fukunaga et al., 1995;
Whitelaw et al., 1993, 1994).
Since the initial cloning of mouse AHR cDNA, cloning has
been accomplished for several other species including rat
(Elferink and Whitlock, 1994), hamster (Korkalainen et al.,
2000), guinea pig (Korkalainen et al., 2001), numerous other
mammalian species, fish, and birds (reviewed in Hahn, 2002;
Hahn et al., 2006). Collectively, cloning studies from multiple
vertebrate species reveal that sequence is highly conserved in
the N-terminal region which contains bHLH/PAS domains
whereas the C-terminal region is much more variable. Later in
this review wewill consider the impact of sequence variation on
AHR function.
Cloning of human AHR cDNA in Chris Bradfield’s labora-
tory (Dolwick et al., 1993) was particularly important because
this opened the possibility of determining, by molecular epide-
miologic studies, whether human AHR polymorphisms might
FIG. 5. General domain organization of the AHR. The AHR has modular
organization in which specific functions are concentrated within particular
domains. Ligands bind the PAS-B domain. Binding to hsp90 involves both the
PAS-B domain and the bHLH domain. Dimerization with ARNT also involves
both the HLH domain and the PAS domains. DNA binding and the nuclear-
localization signal reside in the basic region of the bHLH domain. The trans-
activation function involves a large region toward the carboxy terminus and
contains several subdomains (not shown) (Ko et al., 1997; Reen et al., 2002;
Sogawa et al., 1995). The carboxyl half of the AHR protein shows the greatest
structural variation across different animal species whereas bHLH/PAS do-
mains are highly conserved. (Modified from Gu et al., 2000; Kewley et al.,
2004; Okey et al., 1994b.)
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be associated with the risk of adverse health effects from dioxin-
like compounds (see below).
AHR: THE ESSENTIAL MEDIATOR OF TCDD TOXICITY
Receptor theory is the backbone of pharmacology. The
principles of receptor function have provided mechanistic ex-
planations of great utility in pharmacology and therapeutics for
understanding drug properties such as specificity, potency, and
efficacy.
Although Paul Ehrlich postulated in the late 19th century that
pathogenic microbes possess receptors which might serve as
fruitful targets for toxic therapeutic agents (toxic, that is, to the
microbes), receptor theory is a relative latecomer to the field of
mammalian toxicology. Despite this late start, receptor theory
provides considerable explanatory power regarding mecha-
nisms that underlie toxicities of certain important xenobiotic
chemicals. The AHR was in the vanguard of research that
linked soluble intracellular receptors to xenobiotic toxicity.
The confluence of multiple independent lines of evidence
firmly establishes that essentially all major toxic effects of
TCDD and related dioxin-like substances are mediated by the
AHR. The earliest robust evidence that the AHR mediates
dioxin toxicity arose from structure–activity analyses of dioxin
congeners coupled with mouse genetics.
Ligand Structure in Relation to Toxicity
Quantitative structure–activity relationships. One aspira-
tion of toxicologists is to be able to predict the toxicity of
a compound from its chemical structure alone. There is a vast
literature on the relationship between chemical structure and
biological activity for a wide range of toxicant categories, in-
cluding dioxin-like compounds. Indeed, quantitative structure–
activity relationships (QSAR) constitute one of the foundations
of dioxin research. QSAR principles permeate mechanistic
models as well as dioxin risk assessment.
Prior to structure–activity evaluation of dioxins in relation to
overt toxic endpoints, Alan Poland’s laboratory showed that
induction of AHH was strongly influenced by structure for
small series of chlorinated congeners of dibenzo-p-dioxins,
dibenzofurans, azoxybenzenes, and azobenzenes (Poland and
Glover, 1973b; Poland et al., 1976a). Later the Poland lab-
oratory would show that within categories of dioxin congeners,
brominated biphenyls, and PAHs, the compounds that have the
highest affinity for the AHR also are the most toxic (Poland and
Glover, 1980).
Structure–activity AHR studies took a quantum jump when
the Canadian chemist, Stephen Safe, entered this field. In a true
tour de force, he and his wife Lorna eventually synthesized
essentially all congeners in the families of chlorinated dibenzo-
p-dioxins, dibenzofurans, and PCBs so that individual pure
congeners could be tested for biological activity. Stelvio
Bandiera, an energetic Ph.D. student from the Safe laboratory
(then at the University of Guelph, Ontario) spent a brief time in
my laboratory (then at the University of Windsor) to learn the
AHR binding assay and to begin testing a series of PCB
congeners for their ability to compete with [3H]TCDD for
specific AHR sites. From this study we found that all PCB
congeners tested had some ability to compete with [3H]TCDD
but that competitive potency varied widely. The most potent
competitors were the coplanar congeners, 3,3#,4,4#,5-penta-
chlorobiphenyl and 3,3#,4,4#-tetrachlorobiphenyl, whereas
congeners that were chlorinated in ortho positions were only
weak competitors (Bandiera et al., 1982).
Competitive binding studies with PCB congeners and
concurrent measurements of CYP1A induction allowed pre-
liminary modeling of the molecular features that confer spe-
cific, high-affinity binding and revealed the importance of such
parameters as number of substituent groups, hydrophobicity,
and electronegativity (Safe et al., 1985). Subsequent collabo-
rative studies between the Safe laboratory and my group
suggested that the structural ligand features which are impor-
tant for binding to human AHR differ somewhat from those
that influence binding to receptors from laboratory species
(Golas et al., 1990). The relationship between ligand structure
and toxicity has been thoroughly explored in multiple reviews
by Safe (1986, 1990, 1998a,b) and continues to be an active
area of investigation in his laboratory (Khan et al., 2006).
Some puzzles remain regarding the relationship between
affinity of a compound for the AHR and its potency and efficacy
to stimulate downstream responses. TCDD is a far more potent
AHH inducer than 3-MC—some 30,000 times more potent
in vivo (Poland and Glover, 1974). Higher potency usually
suggests higher affinity for the relevant receptor. However,
when we resumed binding experiments with radiolabeled PAHs
we found, by direct binding assays, that the affinity of [3H]3-
MC for AHR in rodent liver cytosols was very similar to the
affinity with which [3H]TCDD is bound (Okey andVella, 1982).
The vastly greater potency of TCDD is not explained simply by
higher affinity. David Riddick, then a postdoctoral fellow in my
laboratory, conducted a thorough step-by-step comparison of
TCDD and 3-MC in the classic Hepa-1 cell model and found
that 3-MC was essentially equal to TCDD in its affinity for
cytosolic receptor, its ability to transform the AHR to a DNA-
binding state and its initial induction of AHH. However, 3-MC
is rapidly metabolized in vivo or in cells that have active CYP1
enzymes whereas TCDD is highly resistant to metabolism.
This pharmacokinetic behavior accounts for part of the dif-
ference in potency between TCDD and 3-MC (Riddick et al.,
1994); but, in truth, there still is considerable mystery as to
why the gap between TCDD and 3-MC spans many orders of
magnitude.
AHR antagonists. Antagonists can be powerful tools to
identify receptor functions. For several years in the AHR field,
the best available ‘‘antagonists’’ also possessed an undesirable
degree of agonistic activity. Nonetheless, these antagonists/
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partial agonists were able to inhibit, at least to some extent,
biochemical and toxic responses to TCDD in vivo, providing
further evidence for the importance of AHR binding as an early
step in toxicity (reviewed in Okey et al., 1994a). Recently,
there has been a great improvement in development of antag-
onists to probe AHR function. The laboratories of Steve Safe
and Tom Gasiewicz identified flavone derivatives that have a
much improved ratio of antagonist activity to agonist activity
(Henry et al., 1999; Lee and Safe, 2000).
In a very intriguing recent development, Kim et al. (2006b)
screened a large chemical library for compounds that act as
AHR antagonists. They identified a synthetic agent (code
name: CH-223191) that has remarkable ability to block TCDD
binding to the AHR and to prevent downstream events includ-
ing CYP1A1 induction, hepatic toxicity and wasting in vivo.
CH-223191 is devoid of agonist activity for the AHR and ER
and appears to be of low toxicity; thus the authors propose that
this compound might be clinically useful for chemoprevention
of toxicity from dioxin-like compounds.
Pharmacogenetics in Rodents In Vivo
Mouse. Via breeding experiments with mice, Alan Poland’s
laboratory (Poland andGlover, 1980) conclusively demonstrated
that two major in vivo manifestations of TCDD toxicity—
thymic atrophy and cleft palate—segregate with the Ah locus,
i.e., the locus that encodes the AHR (Okey et al., 1979).
At that early stage in AHR research the AHR remained
undetectable in dioxin-resistant mice such as the DBA/2 strain;
hence, it was not possible to compare receptor properties
between dioxin-susceptible and dioxin-resistant mouse strains.
Subsequently, my laboratory developed techniques to charac-
terize stubborn receptors and found that the product of the
mouse Ahrb1 allele (from the prototype C57BL/6 mouse) has
affinity for [3H]TCDD that is about 10-fold higher than the
affinity of the receptor encoded by the Ahrd allele (from the
prototype DBA/2 mouse) (Okey et al., 1989). This relative
difference in affinity for [3H]TCDD was independently con-
firmed by in vitro heterologous expression of cloned variant
AHR structures (Ema et al., 1994) and with a different ra-
dioligand, 2-[125I]iodo-7,8-dibromodibenzo-p-dioxin (Poland
et al., 1994).
The 10-fold lower affinity for TCDD in AHRs of mice
carrying the Ahrd allele leads to a proportional reduction of
about 10-fold in sensitivity for many responses to dioxins
ranging from CYP1A1 induction to lethality, thymic atrophy,
teratogenicity, and hepatic porphyria (reviewed in Nebert, 1989;
Okey et al., 1994a,b, 2005a; Poland and Knutson, 1982), further
implicating the AHR as a major determinant of dioxin toxicity.
Rat. Beginning in the mid-1980s Raimo Pohjanvirta and
Jouko Tuomisto at the National Public Health Institute, Kuopio,
Finland, astutely pursued their original observation that a col-
ony of Han/Wistar rats in Kuopio was extraordinarily resistant
to lethal effects of TCDD (Pohjanvirta and Tuomisto, 1987;
Pohjanvirta et al., 1987). They found that resistance in rat is
inherited as an autosomal dominant trait (Pohjanvirta, 1990);
reviewed in Pohjanvirta and Tuomisto, 1994; Tuomisto, 2005).
With the encouragement of his senior colleague, Jouko
Tuomisto, Raimo came to my laboratory at the University of
Toronto in 1995 with the goal of cloning the AHR from resistant
rats since it seemed probable that their genetic resistance to
dioxin toxicity would reside in some altered AHR property.
Cloning efforts began in Toronto with input from a Ph.D.
student in my laboratory, Judy Wong, along with my Toronto
colleague, Patricia Harper. Our hope for a mechanistic un-
derstanding of the basis for dioxin resistance was fulfilled after
Raimo’s return to Kuopio when he completed the molecular
genetic analysis which revealed that the AHR gene in resistant
H/W(Kuopio) rats contains a mutation at an intron–exon
boundary that unveils cryptic splice sites, leading to deletion
of either 38 or 43 amino acids from the transactivation domain
(TAD) of the AHR protein (Pohjanvirta et al., 1998). Breeding
studies by Jouni Tuomisto (son of Jouko Tuomisto) show that
resistance to TCDD lethality in rat segregates with the variant
Han/Wistar form of the AHR (Tuomisto et al., 1999), again
strongly linking the AHR to dioxin toxicity. Note that in rat,
resistance to TCDD toxicity is inherited as an autosomal
dominant trait, whereas in mouse it is susceptibility that
is inherited as a dominant trait (Okey et al., 2005a). We
will further explore the utility of the resistant rat model for
understanding mechanisms of dioxin toxicity in a later section
of this review.
Birds. Evidence that molecular properties of the AHR are
a major determinant of susceptibility to TCDD was strength-
ened and extended phylogenetically by recent studies in birds.
Chickens are much more sensitive to biochemical and toxic
effects of dioxin-like compounds than are terns. Mark Hahn’s
laboratory found that the reduced sensitivity of terns can be
attributed to the fact that tern AHR has a lower binding affinity
for TCDD than does chicken AHR; consequently, tern AHR
has lesser ability to transactivate gene expression (Karchner
et al., 2006).
AHR Knockout Clinches the Case
Cloning of mouse AHR and deciphering the genomic
organization of the Ahr gene locus (Mimura et al., 1994;
Schmidt et al., 1993) predictably led to efforts by several
laboratories to knock out in vivo AHR function by targeted
gene disruption. Laboratories led by Frank Gonzalez (NIH)
(Fernandez-Salguero et al., 1995), Chris Bradfield (University
of Wisconsin) (Schmidt et al., 1996), and Yoshiaki Fujii-
Kuriyama (then at Tohoku University, Japan) (Mimura et al.,
1997) all succeeded in creating Ahr-null mice.
These knockouts provide unequivocal evidence that the AHR
is crucial to TCDD-induced toxicity. Although the phenotype
differs somewhat among Ahr-null mice from the three
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laboratories (Lahvis and Bradfield, 1998), in each case knock-
ing out the AHR conferred striking resistance to toxicities such
as lethality, immunotoxicity, hepatotoxicity, carcinogenicity,
and teratogenesis (Fernandez-Salguero et al., 1995; Lin et al.,
2001; Mimura et al., 1997; Peters et al., 1999; Thurmond et al.,
1999). Ahr-null mice also are highly resistant to carcinogenicity
from BP (Shimizu et al., 2000).
Note, however, that there is a special exception to the ‘‘rule’’
that the absence of AHR protects from dioxins. Chris
Bradfield’s lab showed that in the case where the mouse
mother is Ahr-null, the embryo is at greater risk of teratogen-
esis, probably due to decreased TCDD clearance leading to
increased TCDD exposure in utero (Thomae et al., 2004). (In
this experiment the embryos were dioxin-susceptible because
they were heterozygous (Ahrþ/) at the Ahr locus.)
The most recent experiments with mice whose AHR path-
ways have been engineered shows that, not only is the AHR
essential to dioxin toxicity, it is the AHR’s transcriptional
regulatory function that is linked to toxicity. The Bradfield
laboratory introduced a mutation which disrupts the AHR
domain responsible for nuclear translocation and binding to
AHRE. TCDD is able to bind to cytosolic AHR in these mice;
but, since they lack nuclear binding of the TCDD–AHR
complex, they are highly resistant to hepatotoxicity, thymic
atrophy, and cleft palate when exposed to TCDD (Bunger et al.,
2003). Moreover, as also shown by the Bradfield laboratory, if
mice are engineered so that they have hypomorphic ARNT
alleles and thus express low levels of ARNT protein, they too
are highly resistant to TCDD toxicity in accord with the AHR’s
inability to alter gene expression when its dimerization partner
is deficient (Walisser et al., 2004a). ‘‘Mouse engineering’’ in
the Bradfield laboratory further reveals that the cell types
involved in AHR-related signaling during liver development
(endothelial/hematopoietic cells) differ from the cell type
(hepatocytes) involved in adaptive and toxic responses to
dioxins (Walisser et al., 2005).
Knockouts and Toxicity as Windows on ‘‘Normal’’ AHR
Functions
AHR knockout studies are valuable, not only because they
demonstrate that dioxin toxicity is AHR-dependent, but also
because they shed some light on normal physiologic functions
of the AHR. One immediate finding from the knockout
experiments was that absence of a functional AHR is not lethal
in mice (Fernandez-Salguero et al., 1995; Mimura et al., 1997;
Schmidt et al., 1996). On the other hand, global knockout of the
AHR’s dimerization partner, ARNT, leads to fetal death at
midgestation, probably due to failed vascular development
since the ARNT protein is an essential participant in hypoxic
signaling by dimerizing with HIF-1a (rather than the AHR)
(Kozak et al., 1997; Maltepe et al., 1997).
In the absence of exposure to dioxins or other exogenous
ligands, Ahr-null mice, although viable, do show abnormalities
in liver development, vascular development, immune function
(reviewed in Lahvis and Bradfield, 1998), and fertility (Baba
et al., 2005). Curiously, the defects in vascular development
that develop in mice which are hypomorphic for AHR or ARNT
can be substantially prevented by exposing these mice to TCDD
in utero; possibly the potent TCDD stimulus is an effective
substitute for a weaker endogenous AHR ligand that lacks
sufficient activating power when levels of AHR or ARNT are
low (Walisser et al., 2004a). It is a truism in biomedical sciences
that ‘‘pathology illuminates physiology.’’ Perhaps by determin-
ing which systems suffer adverse effects from dioxins we might
unveil still more about normal physiologic roles that the
receptor plays. This prospect has been nicely elaborated by
K. Walter Bock in a recent commentary (Bock and Kohle,
2006).
Dioxin Toxicity as the Consequence of Aberrant Gene
Expression
Toxicity from many drugs and environmental chemicals is
due to their enzymatic conversion into reactive metabolites
which covalently attack vital cellular proteins or DNA (Liebler
and Guengerich, 2005). TCDD, however, is highly resistant to
metabolism in most organisms; it is the parent molecule that
does the dirty work. Evidence summarized in the preceding
section shows that the AHR is indispensable to major forms of
dioxin toxicity and that the AHR must be transcriptionally
competent in order for TCDD toxicity to occur.
Our working hypothesis, and that of several other laborato-
ries, is that since the AHR’s main biological function is
transcriptional regulation, TCDD toxicity results from TCDD’s
ability to dysregulate genes that are under control of the AHR.
The questions, then, are (1) what is the full spectrum of genes
that the AHR regulates? (2) Which of these genes does TCDD
dysregulate in a manner that leads to toxicity?
We have known for about two decades that the AHR
regulates enzymes in the CYP1 family along with several other
drug-metabolizing enzymes (reviewed in Nebert et al., 2000).
Foundingmembers of the ‘‘AH gene battery’’ were identified by
what now would seem old-fashioned—the ‘‘one-gene-at-a-
time’’ approach. The first hint that genes other than the ‘‘usual
suspects’’ could be induced by TCDD came from pioneering
efforts of Thomas Sutter and William Greenlee who used
differential hybridization as an unbiased open-ended method to
detect novel dioxin-responsive genes and identified new AHR-
responsive genes that play roles in growth and differentiation
(Sutter et al., 1991). Their experiments (Sutter et al., 1994) also
led to identification of a new P450, CYP1B1, which was
independently discovered by Colin Jefcoate’s laboratory via
protein purification (Savas et al., 1994).
The invention of gene expression arrays and their rapid
technical improvement makes it possible to interrogate es-
sentially the entire transcriptome in one experiment. Several
laboratories, including ours, have applied array technology to
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search for dioxin-responsive and AHR-regulated genes with
the hope of uncovering key pathways to dioxin toxicity
(Boverhof et al., 2005, 2006a; Fletcher et al., 2005; Guo
et al., 2004; Karyala et al., 2004; Martinez et al., 2002; Ovando
et al., 2006; Puga et al., 2000).
Nathalie Tijet and Paul Boutros, research associates in my
lab, used gene array methods in wildtype mice versus Ahr-null
mice to identify the battery of genes that is regulated by TCDD
in the absence of dioxins as well as the batteries of genes that
are dioxin-responsive either in presence of AHR or in Ahr-null
mice (Tijet et al., 2006). Expression of over 450 ProbeSets is
altered in liver by TCDD in an AHR-dependent manner.
Another intriguing finding is that many genes are ‘‘down-
regulated’’ (expression repressed) by TCDD, also in an AHR-
dependent manner. Of course, throughout most of the history
of AHR research the emphasis has been on ‘‘upregulation’’
(induction), not on downregulation. This array study also
showed that very few genes have their expression altered by
TCDD unless the AHR is present, further strengthening the
concept that dioxin toxicity is the result of AHR-mediated
dysregulation of gene expression.
The power of gene expression profiling on arrays is enticing.
Yet, in a curious way, it led to some pessimism about whether
array studies would be helpful in solving the mechanism of
dioxin toxicity. The problem is that hundreds of genes respond
to TCDD. As stated by Alvaro Puga: ‘‘arriving at a sound
understanding of the molecular mechanisms governing the
biological outcome of TCDD exposure promises to be orders of
magnitude more complicated than might have been previously
imagined’’ (Puga et al., 2000). How can we tell which genes
are really central to dioxin toxicity?
Which Genes Matter in Dioxin Toxicity? The
Dioxin-resistant Rat as a Model to Identify Genes
that are Most Relevant to Dioxin Toxicity
The dioxin-resistant H/W (Kuopio) rat strain discovered
by Raimo Pohjanvirta and Jouko Tuomisto (reviewed in
Pohjanvirta and Tuomisto, 1994) provides a potentially power-
ful model for discriminating between genes whose dysregula-
tion is crucial to TCDD lethality versus those genes that are
TCDD-responsive but not involved in lethality. The H/W rat
strain is more than 1000-fold resistant to TCDD-induced
lethality compared with standard laboratory strains due to the
deletion in the AHR TAD described above. The TAD deletion
does not interfere with AHR-mediated induction of genes in the
conventional AH gene battery such as CYP1A1, CYP1A2,
CYP1B1, or UGT1A1 (Okey et al., 2005b). Many chemical
agents that induce CYP1A1 do not cause dioxin-like toxicity
(Hu et al., 2007). We hypothesize that the TAD deletion
selectively alters the AHR’s ability to dysregulate particular
genes that are the key players in dioxin toxicity. In collabora-
tion with Raimo Pohjanvirta and Jouko Tuomisto, two skilled
and highly motivated Ph.D. students in my laboratory, Monique
Franc and Ivy Moffat, employ gene expression arrays to
determine which genes are affected differently by TCDD in
dioxin-sensitive rats (which have wildtype AHR) versus the
highly resistant H/W strain (carrying the TAD deletion). These
array studies reveal that most TCDD-responsive genes are
affected both in sensitive rat strains and in resistant rat strains.
However, some genes are affected only in sensitive rats or only
in resistant rats. We are performing postarray follow-up studies
to attempt to determine if any of the strain-specific responsive
genes can be linked to major dioxin toxicities (Franc et al.;
Moffat et al.; Pohjanvirta et al., in preparation). It is possible
that lethality and other major forms of dioxin toxicity are the
result of concomitant dysregulation of multiple genes rather
than due to changes in a single vital gene; thus we also are
exploring whether dysregulated genes are arranged into
specific functional pathways.
Human AHR Variability and its Effect on Responses
As described above, AHR polymorphisms in rodents can
have a profound impact on the animals’ response to dioxin-like
chemicals (reviewed in Okey et al., 2005b). Hence, it is
worthwhile and important to determine whether genetic
variation also exists in the AHR gene in human populations
and, if so, whether human AHR polymorphisms have signifi-
cant functional consequences. Human variation is an important
issue from the perspective of human risk assessment because
regulations need to be constructed to protect the most
vulnerable members of the population. In collaboration with
David Manchester, we found that there is a greater than 10-fold
range of variation in the human population in the affinity with
which TCDD binds to AHR in placental cytosol but we have
not been able to identify any genetic polymorphisms that
account for this variation in binding affinity (reviewed in
Harper et al., 2002; Okey et al., 2005a).
Our interrogation of the dbSNP (single nucleotide poly-
morphism) database revealed that the density of SNPs across
the full locus is lower for the human AHR gene than for genes
in the formal nuclear receptor superfamily (Okey et al., 2005a).
Conservation of gene structure often suggests that the gene
plays an essential biological role and that evolution does not
tolerate structural variations that interfere with function. As
described earlier, knockout of the Ahr gene is not lethal in
mice. The apparently high degree of sequence conservation in
the human AHR raises the question of whether human AHR
plays some vital role for which there are no backup pathways in
our species (Okey, 2005).
Judy Wong and Maria Lam, graduate students working
jointly with me and with my Toronto colleague Patricia Harper,
diligently searched for novel human AHR polymorphisms and
tested function by transfecting AHR variants into host cells in
culture. The first human AHR polymorphism, at codon 554, was
discovered by Kawajiri et al. (1995) and has been the most
extensively studied. In our assays, the codon 554
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polymorphism, on its own, had no significant effect on CYP1A1
induction by TCDD. However, the TAD wherein the codon 554
polymorphism resides also contains polymorphisms at codon
570 and codon 517 (reviewed in Harper et al., 2002). Our
experiments indicate that the 554Lysine/570Isoleucine combi-
nation or the 554Lysine/570Isoleucine/517Serine haplotype are
poor at sustaining induction of the native CYP1A1 gene by
TCDD in cell culture (Wong et al., 2001b). The 554Lysine/
570Isoleucine/517Serine haplotype seems to be confined to
persons of recent African origin and occurs with low frequency
in the population (Wong et al., 2001b); thus it would be difficult
to conduct epidemiologic studies to determine how this variant
affects health outcomes.
If human susceptibility to dioxin toxicity or to biochemical
effects of dioxins is found to be associated with AHR poly-
morphisms, this would facilitate risk assessment by helping to
establish whether there are individuals in the human population
who might be unusually susceptible to dioxin toxicity due to
genetic variation in their AHR. A few recent epidemiologic
studies (Table 1) suggest that the AHR genotype affects relative
risk for health outcomes such as breast cancer, lung cancer,
hypertension, and birth weight in offspring of smoking mothers
but these studies require replication before firm conclusions
can be drawn. To date, the overall impact of genetic variation in
human AHR on biochemical responses or health outcomes
appears modest.
AHR Activity: Balancing the Good and the Not-so-Good
Given that in the absence of the AHR there essentially is no
toxicity from dioxin-like chemicals, it might be tempting to
conclude that humans (and other vertebrates) would be better
off without an AHR. As an added bonus, not having an AHR
prevents cancer induction by BP, presumably because CYP1A1
can no longer be induced and thus is not available to bioactivate
BP into its ultimate carcinogenic form (Shimizu et al., 2000).
From an evolutionary perspective, there must be advantages to
possessing an AHR. The adaptive and developmental roles
elaborated by the Bradfield laboratory (Walisser et al., 2004b),
on balance, appear to outweigh the deleterious effects of the
AHR’s role in mediating toxicity.
Early in this review I described how my interest in enzyme
induction arose from our discovery that the pesticide, DDT,
could protect rats from cancers when they were exposed to the
PAH carcinogen, DMBA (Silinskas and Okey, 1975), pre-
sumably because DDT stimulates enzymes that aid the rat to
detoxify and eliminate the carcinogen. The fact that induction
of P450s might protect animals from xenobiotic toxicants was
contrary to the prevailing view in the 1960s, 1970s and 1980s
that increased P450 activity is predominantly harmful to
animals exposed to precarcinogens because P450s can bio-
activate pretoxicants and precarcinogens into chemically
reactive intermediates that covalently bind cellular macro-
molecules, thereby initiating mutagenesis, carcinogenesis,
teratogenesis, and a host of related pathologies. There is no
question that the ‘‘reactive metabolite’’ model explains how
many chemicals become harmful.
But it is equally true that the strategy of using enzyme
inducers as chemopreventive agents to reduce cancer risk has
been recognized for several decades (reviewed in Conney,
2003a; Okey, 1990, 2005). Recently, a renewed appreciation
has developed for the benefits conferred by AHR-mediated
enzyme induction (reviewed in Nebert and Dalton, 2006;
Nebert et al., 2004). Eventually, it might be possible to use
pharmacologic or molecular tools to manipulate AHR path-
ways to protect from dioxin-like chemicals. However, agents
that are protective in one biological context may enhance
toxicity or carcinogenesis in another setting. Our current un-
derstanding of AHR pathways is too primitive to allow us to
safely tip the balance strongly in the direction of protection.
Implications of a Receptor-Mediated Mechanism for
Risk Assessment
Just how great is the risk to human health from dioxin-like
chemicals? There is no clear consensus on the answer to this
vital question, particularly for the cancer endpoint. Dioxin risk
assessment is fraught with controversy (Cole et al., 2003;
Connor and Aylward, 2006; Gough, 2003; Guzelian et al.,
2006; Starr, 2003; Tuomisto, 2005) and I don’t presume that my
experience in AHR research can cast much additional light into
this dark corner. Nevertheless, a few reflections might be in or-
der because of the central role the AHR plays in dioxin toxicity.
We established that the AHR mechanism is available in
humans to potentially mediate the same functions that it does in
laboratory animals, albeit with notable differences in species
sensitivity. Dioxin-like chemicals are the first major toxicant
class to undergo extensive risk assessment founded on the
premise that their toxicity is initiated by binding to a soluble
receptor—in this case, the AHR. The United States Environ-
mental Protection Agency’s Draft Dioxin Reassessment (high-
lights and summary at US-EPA, 2004) has been a lightning rod
for criticism on specific points but also a useful catalyst to
stimulate thoughtful and vigorous debate on risk assessment for
the important dioxin class of toxicants. Lessons learned in the
AHR/dioxin system also may facilitate risk assessment for
environmental toxicants that act on other nuclear receptors such
as the ER or androgen receptor.
Classic receptor theory, in conjunction with empirical
observations in multiple receptor systems, makes certain pre-
dictions about how receptor-mediated responses ought to
behave. Implications of receptor theory for dioxin risk assess-
ment have been clearly enunciated in previous commentaries
by Poland (1996, 1997). Among the issues raised by a receptor-
mediated mechanism are the following.
Dose–response relationships and thresholds. The cloudiest
and most contentious issue in dioxin risk assessment concerns
the shape of the dose–response curve for adverse effects of
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TABLE 1
Reported Effects of Human AHR Polymorphisms on Various Outcomes
Polymorphic site(s) Assay or endpoint Outcome Ethnic group Reference
AHR coding region variants
R554K AHH induction in PBL No effect Japanese (Kawajiri et al., 1995)
R554K EROD induction in PBL Increased with 554K Caucasian (Smart and Daly, 2000)
R554K CYP1A1 level in lung No association Finnish (Anttila et al., 2000)
R554K CYP1A1 level in lung No association Caucasian (Anttila et al., 2001)
R554K EROD activity in lung No association Caucasian (Smith et al., 2001)
R554K CYP1A1 induction in PBL No effect mouse cell (Wong et al., 2001a)
R554K EROD induction in PBL No effect French (Cauchi et al., 2001)
R554K Lung cancer risk No association French (Cauchi et al., 2001)
R554K Chloracne No association Caucasian (Wanner et al., 1999)
R554K Bladder cancer risk No association Chinese (Zhang et al., 2002)
R554K Endometriosis risk No association Japanese (Watanabe et al., 2001)
R554K Micropenis risk No association Japanese (Fujita et al., 2002)
R554K Reporter gene induction No effect human cell (Koyano et al., 2005)
R554K Soft tissue sarcoma survival Shortened with 554K Caucasian (Berwick et al., 2004)
R554K Breast cancer risk Decreased with 554A Chinese (Long et al., 2006)
R554K Sperm Y:X chromosome ratio No association Swedish (Tiido et al., in press)
R554K Blood pressure in smokers No effect French (Gambier et al., 2006)
R554K Chloracne No effect Taiwanese (Tsai et al., 2006)
R554K (maternal) Recurrent pregnancy loss No association Japanese (Saijo et al., 2004)
R554K (maternal) Offspring size from
smoking mothers
Decreased with 554R/R* Japanese (Sasaki et al., 2006)
R554K DNA damage in PBL from
coke oven workers
Increased with 554K Chinese (Chen et al., 2006)
R554K; V570I EROD induction in PBL Increased with 554K African (Smart and Daly, 2000)
R554K; V570I CYP1A1 induction Decreased Mouse cell (Wong et al., 2001b)
P517S;R554K; V570I CYP1A1 induction Decreased Mouse cell (Wong et al., 2001b)
K401R Reporter gene induction Reduced induction with 401R Human cell (Koyano et al., 2005)
N487D Reporter gene induction Reduced induction with 487D Human cell (Koyano et al., 2005)
I514T Reporter gene induction No effect Human cell (Koyano et al., 2005)
K17T/R554K Reporter gene induction No effect Human cell (Koyano et al., 2005)
K17T Reporter gene induction No effect Human cell (Koyano et al., 2005)
AHR promoter region variants†
 552 T > C Reporter gene induction No effect Human cell (Racky et al., 2004)
 385 A > G Reporter gene induction No effect Human cell (Racky et al., 2004)
 230 G > A Reporter gene induction No effect Human cell (Racky et al., 2004)
 196/ 195 DGG Reporter gene induction No effect Human cell (Racky et al., 2004)
 195 DG Reporter gene induction No effect Human cell (Racky et al., 2004)
 137 C>T Reporter gene induction No effect Human cell (Racky et al., 2004)
þ 119 C > G Reporter gene induction No effect Human cell (Racky et al., 2004)
þ 157 G > A Reporter gene induction No effect Human cell (Racky et al., 2004)
þ 157 G > A EROD induction in PBL No effect French (Cauchi et al., 2001)
Combination of polymorphisms
R554K and CYP1A1 T3801C Blood pressure Increased with 554K þ CYP3801C
in ex-smokers and nonsmokers
French (Gambier et al., 2006)
Ex1 þ 185A > G and‡ IVS7 þ 33T > G
and Ex10 þ 501G > A (¼ R554K)
Lung cancer risk in smokers Increased with GGG haplotype Korean (Kim et al., 2006a)
Note. Arg/Arg (abbreviated R) is considered to be the wildtype for human AHR and lysine the variant (abbreviated K). EROD ¼ ethoxyresorufin O-deethylase;
PBL ¼ peripheral blood lymphocytes. Mouse cell ¼ activity tested with human AHR constructs transfected into an AHR-deficient mouse cell line. Human cell ¼
activity tested with human AHR constructs transfected into a human cell line.
*The effect of polymorphism at codon 554 of the AHR gene on birth weight and birth length was greatest effect when the 554 polymorphism was present in
combination with a variant allele in the CYP1A1 gene.
†There is considerable confusion regarding the location of these promoter variants. For example, variant rs7796976 has been identified variously as being
located at position þ 185 (Kim et al., 2006a); Entrez dbSNP build 126, or at position þ 157 (Cauchi, 2001; Racky, 2004), whereas the current refseq
(NM_001621.3, 14 January 2007) places this SNP at þ 124.
‡Ex1 þ 185A > G is rs7796976; IVS7 þ 33T > G is rs2074113; and Ex10 þ 510G > A is rs2066853 (R554K).
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dioxins at environmentally relevant exposure levels. This is
coupled with the question of whether a threshold exists, below
which there is no significant increase in risk for cancer or other
adverse health effects. Analytical improvements provide the
means to measure human exposure at ever-lower levels (Reiner
et al., 2006) but also place more demands on the risk assess-
ment process to know what these ultralow levels mean for
human health.
Dose–response relationships lie at the heart of pharmacology
and are underpinned by receptor theory. Receptor theory and
numerous empirical precedents predict that responses should be
sublinear at low doses and that a practical threshold should exist
(Poland, 1997). The EPA Dioxin Reassessment draft document
(US-EPA, 2004) concludes that AHR-mediated biochemical
responses ‘‘are likely to demonstrate low-dose linearity’’—in
other words, no threshold. However, the National Academies of
Science review of the draft document holds that ‘‘EPA’s
decision to rely solely on a default linear model lacked adequate
scientific support’’ (NatAcadSci, 2006). The heart of the
problem in defining the shape of the dose–response curve at
environmentally relevant levels is that valid, experimentally
derived data are virtually impossible to obtain at these ultralow
exposure levels; hence, the risk assessment continues to default
to a linear multistage model. Some investigators such as
Michael Schwarz and Klaus Appel believe that there is
sufficient evidence to move away from the linear model for
dioxins; they propose ‘‘for regulatory purposes the application
of a so called ‘practical threshold’ for the carcinogenic effect’’
(Schwarz and Appel, 2005). As stated by others (Poland, 1997;
Schwarz and Appel, 2005), the current linear multistage
approach to risk is a policy decision rather than a scientific
decision based on actual data from responses at very low dioxin
levels. Any clever new approach that can experimentally
resolve the nature of the dose–response curve at ultralow
in vivo levels clearly would be welcomed but the prospects
for such a breakthrough seem dim.
The toxicity of mixtures: toxic equivalency factors and toxic
equivalencies. Dioxin-like chemicals exist in the environment
as complex mixtures including polychlorinated dibenzo-p-
dioxins, polychlorinated dibenzofurans, and PCBs along with
a multitude of nonhalogenated AHR ligands. For real-world
risk assessment it’s necessary to take into account the con-
tributions made by the combination of AHR ligands, not just
TCDD alone. Thus, was born the concept of using ‘‘toxic
equivalency factors’’ (TEFs) in which each congener is as-
signed a TEF that reflects the best estimate of its toxicity
relative to that of 2,3,7,8-TCDD. Overall toxicity of a mixture is
termed the TEQ (toxic equivalency) which is assumed to be
equal to the sum of the concentrations of individual congeners
multiplied by their TEFs (Safe, 1997; Van denBerg et al., 2006).
The central premise in the TEF/TEQ approach is that the
cumulative toxic effects of components in a mixture are
additive. There is experimental evidence to support the
assumption of additivity (Viluksela et al., 1998; Walker et al.,
2005). However, receptor theory predicts that compounds
which compete for the same receptor site will antagonize each
other if the mixture contains partial agonists; some studies
have, indeed, found antagonism (Haag-Gronlund et al., 1998;
Hestermann et al., 2000; Safe, 1998a; Van Birgelen et al.,
1994). In other words, the TEQ approach can, at least some-
times, overestimate the toxic potency of a mixture.
Assignment of the appropriate TEF for each congener is
challenging because different biochemical and toxic responses
may have very different dose–response curves, even within the
same animal (Starr et al., 1999). Therefore, the relative potency
estimates for dioxin-like compounds are undergoing continual
refinement (Budinsky et al., 2006; Haws et al., 2006).
Although some aspects of the TEQ concept are at variance
with expectations from receptor theory, in practice the TEQ
approach is pragmatic and appears to make reasonably accurate
predictions about the overall toxicity of mixtures as reflected in
the most recent report from the World Health Organization
Expert Panel on TEFs (Van den Berg et al., 2006).
Reversibility. In principle, responses mediated by interac-
tion of a ligand with its receptor are reversible when the ligand
is withdrawn because response depends upon continued
presence of the ligand–receptor complex. For most therapeutic
agents the duration of response is a few hours or few days. Drug
effects wane and terminate as metabolism fosters elimination of
the drug. To the pharmacokineticist (accustomed to thinking of
clearance in units of hours or days), TCDD is a bizarre
compound because its half-life in humans is measured in years.
Therefore, in humans this AHR ligand potentially is available to
stimulate responses almost in perpetuity. Perhaps, then, TCDD-
induced responses should be considered essentially irreversible
(Schwarz and Appel, 2005) even though they are receptor-
mediated. TCDD remains on board in humans for a very long
time but, in truth, we know relatively little about its ability to
access the AHR and continue to drive biochemical responses or
overtly toxic responses. We do know that the skin disorder,
chloracne, that occurs in some persons exposed to high dioxin
levels can persist for years (Geusau et al., 2001; Panteleyev and
Bickers, 2006).
Tissue specificity. For therapeutic agents that act via
receptors there is an expectation that the effect will be limited
to a particular ‘‘target’’ tissue or cell type, i.e., those cells that
have the appropriate receptor. As described above, the AHR has
a remarkably broad pattern of expression in vertebrate species,
tissues, and cell types. In principle, therefore, almost all
vertebrate tissues could be targets for toxic effects of dioxin-
like chemicals. However, particular cell types and tissues are
preferentially damaged by dioxins and these are not necessarily
the same across various mammalian species. It is not simply
a matter of the level of AHR expressed in each tissue. Just as we
do not yet fully understand the basis for species differences in
susceptibility to dioxin-like chemicals, we also have a profound
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lack of insight into what makes certain tissues highly suscep-
tible to dioxin toxicity and what makes some ‘‘privileged’’
tissues highly resistant.
Enduring Mysteries
Dioxin toxicity continues to be an intriguing and high-profile
jumble of science, policy, politics, economics, and societal
values (Stone, 2007). After 30 years of AHR research, where
has the voyage taken us in regard to understanding dioxin
toxicity? I titled this essay ‘‘. . . to the Shores of Toxicology’’
because, although the sturdy and trusty AHR ship has brought
us tantalizingly close to our objective of understanding mech-
anisms of gene regulation and dioxin toxicity, in truth, we have
only just landed on the shore. Our quest for the mediator of
dioxin’s biochemical and toxic effects has let us glimpse many
important and fundamental AHR attributes through gaps in the
fog. But, as is perpetual in science, beyond the shore lies terra
incognita.
We all love a good mystery when it’s presented to us as
a clever work of fiction in books or on screen. However, the
scientist in us wants the answer—preferably as soon as possible
(and before anyone else solves the puzzle). Research on the
AHR and dioxin toxicity retains many unknowns. I believe that
we have partial answers (as addressed throughout this review)
to the questions below; but these issues beg for a more
comprehensive understanding to place our science on a firmer
footing.
What accounts for the striking differences in susceptibility
to dioxin toxicity among mammalian species? Is susceptibility
determined mainly by properties of the AHR?. One of the
durable mysteries regarding dioxin toxicity is why there are
such profound differences in susceptibility among mammalian
species (Bock and Kohle, 2006). I know of no instance in
small-molecule toxicology, other than TCDD, where species
differences in sensitivity span several orders of magnitude.
I also know of no other small-molecule toxicant that exerts
such a broad range of severe toxicities in a wide variety of lab-
oratory animals and yet has so few conclusively demonstrated
serious adverse effects on human health. The sensitivity of
standard mammalian laboratory species to dioxin toxicity is
truly alarming. Extrapolation of animal toxicity data to humans
is a traditional mainstay in risk assessment. However, the toxic
endpoints (e.g., wasting, death, hepatic toxicity, teratogenesis)
that are hallmarks of dioxin toxicity in laboratory species are
not prominent in humans exposed to dioxins through occupa-
tion, accident or diet.
The US-EPA draft Dioxin Reassessment Scientific High-
lights state that ‘‘humans may fall in the middle of the range of
sensitivity for individual effects among animals’’ and that
‘‘humans, in general, are neither extremely sensitive nor
insensitive to the individual effects of dioxin-like compounds
as compared to other animals.’’ In my opinion, the available
evidence from epidemiology and from assessment of bio-
chemical responses to TCDD locates humans towards the
dioxin-resistant end of the spectrum among mammalian
species. We have measured TCDD binding to AHR along with
CYP1A1 induction in several human cell lines in comparison
with the benchmark mouse cell line, Hepa-1 (which carries the
Ahrb1 allele). As illustrated in Figure 6, both the receptor
occupancy curve and the dose–response curve for subsequent
induction of CYP1A1 are shifted about one log unit to the right
for human cells versus mouse Hepa-1 cells. Multiple human
cell lines that we tested all are 5- to 10-fold less sensitive than
Hepa-1 mouse cells for receptor affinity and/or for CYP1A1
induction (Harper et al., 1988, 1991b; Roberts et al., 1990;
Waithe et al., 1991). Ramadoss and Perdew (2004) used the
photoaffinity ligand, 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-
dioxin and also found, by studies with expressed receptor pro-
teins in intact cells, that at a given radioligand concentration,
human AHR bound about 10-fold less ligand than did the
product of the mouse Ahrb1 allele.
Studies on human cell lines provide AHR characteristics for
only a few donors. Hence we took advantage of the high AHR
abundance in human tonsils and human placenta to measure
[3H]TCDD binding affinity (Kd) in human populations. Within
these populations there was greater than a 10-fold range in
binding affinity (Harper et al., 2002; Lorenzen and Okey, 1991;
Okey et al., 1997). Many donors exhibited low affinity with Kd
values near that of AHR from nonresponsive mice. Connor and
Aylward (2006) have used the term ‘‘impaired’’ to describe the
apparently lowered functionality of human AHR and this
appears apt for many samples. However, some individuals in
the human population express an AHR that has affinity for
TCDD near that of susceptible rodents such as C57BL/6 mouse
or Sprague–Dawley rats (Harper et al., 2002; Lorenzen and
Okey, 1991).
Do structural features of the AHR account for its varied
functions in different animal species? In certain laboratory
animal models, described earlier (such as C57BL/6 vs. DBA/2
mice or the Han/Wistar(Kuopio) rat), sensitivity or resistance to
TCDD clearly is related to properties of the AHR (Okey et al.,
2005b). However, there also are differences in susceptibility
between laboratory species that remain unexplained. For exam-
ple, AHRs have been cloned from guinea pig (Korkalainen
et al., 2001) and hamster (Korkalainen et al., 2000); this clon-
ing provides hints to how differences in AHR structure might
affect AHR function and dioxin sensitivity but we still do not
truly understand why guinea pig is highly susceptible to TCDD
lethality, whereas hamster is exceptionally resistant.
The primary structure, determined by cDNA cloning or
genomic sequencing, is now available for many mammalian
species. However, the AHR protein has stubbornly resisted
attempts to crystallize it and to obtain high-resolution 3-D
structures. Homology modeling of the AHR ligand-binding
domain gives some insight into the means by which the AHR
recognizes ligands (Pandini et al., 2007) and provides support
for previous findings (Ema et al., 1994; Poland et al., 1994) that
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substitution of valine for alanine at position 375 substantially
reduces the affinity of TCDD binding. However, much remains
to be done in solving the crystal structure to a resolution that
will permit real understanding of AHR interactions with
ligands, other proteins, and DNA and how these might differ
among species.
Overall it appears that some portion of the relative in-
sensitivity of the human species likely is due to the lower
affinity with which human AHR binds TCDD when compared
with affinities in most rat and mouse strains (Harper et al.,
2002) but it is unlikely that the difference in affinity alone
accounts for all the differences in toxic outcomes in humans
versus rodent models. There also are likely to be species
differences and individual differences in pathways downstream
of initial ligand binding which strongly influence dioxin
susceptibility but these have not been extensively explored.
Production of ‘‘AHR-humanized mice’’ provides one strat-
egy to determine whether properties of the AHR itself are the
main determinant of sensitivity to biochemical and toxic effects
of dioxins. Moriguchi et al. (2003) (Tsukuba, Japan) succeeded
in inserting human AHR into mice in place of the normal mouse
Ahr alleles. Mice that express human AHR in vivo are less
susceptible to TCDD-induced cleft palate than mice that are
homozygous for either the mouse Ahrb1 ‘‘high affinity’’ allele or
the mouse Ahrd ‘‘low-affinity’’ allele. These AHR-humanized
mice open the opportunity to further dissect similarities and
differences between mouse and human AHRs in their ability to
drive biochemical, cellular, and toxic responses to dioxins and
other AHR ligands.
Why don’t all high-affinity AHR ligands produce dioxin-like
toxicity?. Simple receptor theory predicts that all chemicals
that are agonists for the same receptor should produce re-
sponses that qualitatively are the same. The difference among
agonists should lie in the quantitative parameters of potency
and efficacy, not the qualitative nature of the response elicited.
As described above, there is a plethora of known AHR agonists
from a very broad variety of chemical classes. Fortunately, few
of these agents provoke dioxin-like toxicity. For example, sev-
eral compounds of plant/dietary origin are potent AHR agonists
in various in vitro assays but they do not mimic TCDD in regard
to toxicity (Denison et al., 2002). The usual explanation for this
discrepancy between AHR activation and toxicity is a pharma-
cokinetic one: many natural products that bind the AHR are
rapidly metabolized and have short half-lives in vivo. Yet phar-
macokinetics alone cannot fully explain what properties make
an AHR agonist highly toxic. Some insight into this puzzle may
come about from determining how each ligand induces a spe-
cific conformation in the AHR protein and how this conforma-
tion permits the ligandedAHR to selectively recruit coactivators
or corepressors that tune the spectrum of ultimate responses
with great subtlety. For example, Henry and Gasiewicz (2003)
have shown that agonists produce a different conformation of
the AHR protein than do antagonists. Stephen Safe has
pioneered the concept of ‘‘SAhRMS’’; that is, selective AHR
modulators whose structures elicit AHR-mediated responses
that are therapeutically beneficial rather than toxic (Liu et al.,
2006; Safe and McDougal, 2002). Structure–activity relation-
ships for the AHR, its ligands and responses have been
FIG. 6. Comparison of a human cell Line with a mouse cell line for TCDD receptor binding and CYP1A1 induction. The left-hand panel represents the extent
of [3H]TCDD-specific binding to cytosol from the mouse Hepa-1 cell line (Ahrb1 allele) and the human LS180 cell line over a wide range of radioligand
concentrations. The right-hand panel represents dose–response curves for induction of CYP1A1 (measured as aryl hydrocarbon hydroxylase activity) in these same
cell lines. The shift-to-the-right of about one log unit in the occupancy curve for TCDD binding to AHR (left panel) is similar in magnitude to the shift in the
downstream response, CYP1A1 induction (right panel). Although the curves for CYP1A1 induction differ between mouse Hepa-1 cells and human LS180 cells in
proportion to receptor occupancy, this does not necessarily indicate that all AHR-mediated gene responses will show the same difference between species. (Data
replotted from Harper et al., 1991b.)
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studied for more than 25 years but there still is much to learn in
this area.
Which specific genes are dysregulated by dioxins in a
fashion that leads to major toxicities?. As described earlier,
there is strong evidence that the major forms of dioxin toxicity
are due to dysregulation of gene expression mediated by the
AHR but we do not know which specific genes are the key to
different toxic manifestations. This is a major focus of current
research in my laboratory. It is unlikely that a single molecular
or biochemical response triggers the myriad diverse toxic
outcomes from dioxin exposure. Varied toxic endpoints prob-
ably share some initial triggering events but each endpoint
(wasting, lethality, hepatotoxicity, immunotoxicity, reproduc-
tive toxicity, developmental toxicity, etc.) likely is due to
distinct (but overlapping) sets of dysregulated genes. Fortu-
nately, there are many laboratories using expression arrays to
map the sets of genes that respond to dioxin-like chemicals at
different times, at different doses and in various species, tissues,
and cells. Interpretation of these large data sets is not trivial but
we can anticipate that central principles will begin to emerge
from this concerted effort.
What is the full extent of the AHR’s normal biological
function – during development and in adult life and what is the
full range of endogenous ligands?. Answers to these ques-
tions are inextricably linked to understanding dioxin toxicity.
Toxic responses help to illuminate physiologic functions but, in
turn, a more mature understanding of the AHR’s physiologic
roles will greatly aid toxicology. Is there a single ‘‘master’’
endogenous ligand? Or do physiologic functions of the AHR
involve different ligands in different tissues at different times
(Bock and Kohle, 2006)?
What factors steer AHR-mediated responses to one or more
of the three general paths enunciated by the Bradfield
laboratory (adaptive, developmental, toxic)?. How does
signaling that begins with ligand binding in cytoplasm end
up producing divergent responses that sometimes foster normal
development, sometimes help adapt to external challenges, or
sometimes are overtly toxic (Walisser et al., 2004a)? The
choice of pathway is strongly influenced by the nature of the
chemical ligand but we need to know much more about how
varied characteristics of the biological substrate shape the
ultimate response. For example, what is the repertoire of
coactivators and corepressors within a particular cell type? Are
the components in the signaling pathway stable over time or are
they altered by other endogenous and exogenous stimuli?
How important are protein–protein interactions in the
AHR’s normal biological functions and in toxicology?. In
the ‘‘standard model’’ of dioxin toxicity (described above),
dioxin-like chemicals must bind the AHRwhich then dimerizes
with ARNT and alters gene transcription. Several investigators
have shown that the AHR undergoes direct protein–protein
interactions, not only with ARNT, but also with other key
regulatory proteins. Most notably, when activated by TCDD,
the AHR forms a complex with the retinoblastoma protein (RB)
which inhibits transcription of E2F-dependent genes leading to
subsequent arrest of the cell cycle (reviewed in Huang and
Elferink, 2005; Marlowe and Puga, 2005; Puga et al., 2002). In
this instance, interaction of the AHR with the RB protein
represses gene expression rather than the conventional en-
hancement of gene expression observed following dimerization
with ARNT. In addition to direct interactions with the RB
protein, the AHR also has been shown to interact with NF-jB,
a powerful regulator of diverse cell functions (Tian et al.,
1999, 2002).
Literature on the AHR’s protein–protein interactions and role
in the cell cycle is derived almost entirely from experiments
done in cell culture. Responses of cells in their normal in vivo
context can differ substantially from what is seen with in-
dividual cell types alone in culture. It is important to determine
whether the responses in cell culture accurately reflect how
cells respond in vivo to signals via AHR protein–protein
pathways. This is especially relevant to the potent tumor
promoting activity of TCDD which is tied to altered cell
proliferation and apoptosis (Bock and Kohle, 2005). As a step
toward understanding in vivo effects of TCDD and AHR on cell
cycle and cell proliferation the Elferink laboratory recently
employed the regenerating rat liver model and found that when
AHR activation is sustained by TCDD exposure, hepatic growth
is attenuated (Mitchell et al., 2006). However, it is not yet clear
whether alteration of cell proliferation in vivo is dependent
primarily on the ‘‘standard’’ transcriptional activity of the AHR
or whether it is driven by protein–protein interactions such as
with RB protein. If in vivo experiments can be designed that can
distinguish between these two regulatory arms, they would be
of great value for understanding normal biological functions of
the AHR along paths of dioxin toxicity.
Full circle: how did AHR and ER pathways come to be so
intertwined?. As I described in the opening to this story, my
first independent research was devoted to interactions of ‘‘MC-
type’’ PAHs (AHR agonists) with the ER. When our research
on AHR took off, my laboratory discontinued work on ER.
Little did we realize that interactions between AHR pathways
and ER pathways would become an area of keen interest to
toxicologists. In the late 1980s, Michael Gallo’s laboratory and
Stephen Safe’s laboratory tested the effects of TCDD on
uterine tissue and found that TCDD was predominantly
antiestrogenic (Umbreit and Gallo, 1988; Umbreit et al.,
1988); reviewed in (Safe and Wormke, 2003).
However, emphasis over the past few years has shifted to the
ability of AHR ligands to act as estrogens rather than
antiestrogens, stimulated in large part by a paper from Ohtake
et al. (2003) who postulated that ligand-activated AHR func-
tions as a coactivator of ERa to stimulate estrogen targets.
Subsequent studies in other laboratories indicate that TCDD
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and several additional AHR agonists can directly bind and
activate ER rather than requiring the AHR to function as a
coactivator (Abdelrahim et al., 2006; Boverhof et al., 2006b;
Shipley and Waxman, 2006).
So perhaps the passing structural similarities between AHR
agonists and estrogens (Fig. 1) do, in fact, permit AHR ligands
to cross-activate the ER. However, activation of ER by AHR
ligands such as 3-MC, BP, or PCBs requires concentrations in
the micromolar range (Liu et al., 2006). Environmental and
dietary exposures to dioxin-like compounds do not typically
lead to plasma concentrations in the micromolar range. Thus,
although AHR ligands can, in principle, activate ER, it is not
established that these interactions are important for endocrine
function, reproduction, and toxicology.
Finally, just to show that cross-talk in signaling pathways
rarely is simple and straightforward, the ARNT protein has
been shown to be a coactivator of ER-dependent transcription
(Brunnberg et al., 2003), whereas TCDD inhibits some estro-
genic responses such as upregulation of ERb by ERa (Kietz
et al., 2004). Moreover, for some genes such as CYP1A1, AHR
appears to be able to recruit ERa into the promoter region,
perhaps explaining the estrogen-dependent nature of CYP1A1
FIG. 7. Time-line of key discoveries related to the AHR. See the text for details.
FIG. 8. Growth of literature related to the AHR. Data from 1980 through
2006 represent the number of papers retrieved for each year from a PubMed
search using the terms: ‘‘aryl hydrocarbon receptor’’ or ‘‘dioxin receptor.’’ The
AHR is not necessarily the primary focus of each of these papers nor has the
number of AHR publications been normalized to the total number of papers
published in the biomedical literature for each year. The number of AHR papers
listed from 1976 until 1980 is based on my reprint files of papers that appeared
during the inaugural years of research in the AHR field.
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induction in some cell lines (Matthews and Gustafsson, 2006;
Matthews et al., 2005) although it also has been reported that
the ERa which is recruited to the CYP1A1 promoter functions
as a repressor of transcription rather than as a coactivator
(Beischlag and Perdew, 2005).
At present, it is impossible to make a simple summary of
how AHR and ER pathways intersect. Determining the re-
sultant of the push–pull interactions between AHR and ER
pathways, under conditions of real-world exposure, is impor-
tant and should keep investigators in this field busy for several
years to come.
CONCLUSION: RETURN ON INVESTMENT
We frequently tell our students (and, sometimes, granting
agencies and governments) that if we understand the mecha-
nism by which a toxicant acts, we will be able to make a much
more accurate and valid assessment of the risk which that
toxicant poses to human health and health of the ecosystem. As
stated by Conolly (2002), research on mechanisms of toxic
action serves to reduce uncertainty in risk assessment. How-
ever, mechanistic understanding is not, on its own, sufficient to
define risk—a point eloquently made by Prof. Jouko Tuomisto
in his Deichmann Lecture in 2004 (Tuomisto, 2005). Never-
theless, I believe that the AHR research community can
legitimately claim, with pride (and without apology or embar-
rassment), that our collective mechanistic discoveries during
the past 30 years (Fig. 7) are providing an invaluable scientific
foundation for assessing human health risks.
Research on the AHR shows no signs of waning (Fig. 8).
Much remains to be done, both in basic AHR science and
regarding its role in environmental health. It’s tempting, when
concluding an overview such as this, to make predictions about
the future of the field. Of course such prognostications carry
their own risk—that of being nothing more than fool-hardy, ill-
informed failures. Given the pace of current science, I’m
confident, however, that we will not need to wait another 30
years for solutions to most of the mysteries listed above. We
also should anticipate a few more surprises, twists, and turns in
the AHR story along the way.
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